204 results on '"Meert AP"'
Search Results
2. Post-chemotherapy heat stroke during the hottest week of the year
- Author
-
Catherine, J, primary, Geelhand, M, additional, and Meert, AP, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Performance of the ROX index to predict intubation in immunocompromised patients receiving high-flow nasal cannula for acute respiratory failure
- Author
-
Lemiale, V, Dumas, G, Demoule, A, Pène, F, Kouatchet, A, Bisbal, M, Nseir, S, Argaud, L, Kontar, L, Klouche, K, Barbier, F, Seguin, A, Louis, G, Constantin, JM, Mayaux, J, Wallet, F, Peigne, V, Girault, C, Oziel, J, Nyunga, M, Terzi, N, Bouadma, L, Lautrette, A, Bige, N, Raphalen, JH, Papazian, L, Bruneel, F, Lebert, C, Benoit, Dominique, Meert, AP, Jaber, S, Mokart, D, Darmon, M, Azoulay, E, de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (GRRR-OH, Groupe, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Picardie Jules Verne (UPJV), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Oxygenation index ,high-flow nasal oxygen ,medicine.medical_treatment ,Acute respiratory failure ,Critical Care and Intensive Care Medicine ,medicine.disease_cause ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Anesthesiology ,Medicine and Health Sciences ,medicine ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Intubation ,Immunocompromised ,acute respiratory failure ,business.industry ,Research ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,Correction ,030208 emergency & critical care medicine ,lcsh:RC86-88.9 ,High-flow nasal oxygen ,medicine.disease ,3. Good health ,Pneumonia ,immunocompromised ,030228 respiratory system ,Anesthesia ,Economie ,business ,Nasal cannula - Abstract
Background: Delayed intubation is associated with high mortality. There is a lack of objective criteria to decide the time of intubation. We assessed a recently described combined oxygenation index (ROX index) to predict intubation in immunocompromised patients. The study is a secondary analysis of randomized trials in immunocompromised patients, including all patients who received high-flow nasal cannula (HFNC). The first objective was to evaluate the accuracy of the ROX index to predict intubation for patients with acute respiratory failure. Results: In the study, 302 patients received HFNC. Acute respiratory failure was mostly related to pneumonia (n = 150, 49.7%). Within 2 (1–3) days, 115 (38.1%) patients were intubated. The ICU mortality rate was 27.4% (n = 83). At 6 h, the ROX index was lower for patients who needed intubation compared with those who did not [4.79 (3.69–7.01) vs. 6.10 (4.48–8.68), p < 0.001]. The accuracy of the ROX index to predict intubation was poor [AUC = 0.623 (0.557–0.689)], with low performance using the threshold previously found (4.88). In multivariate analysis, a higher ROX index was still independently associated with a lower intubation rate (OR = 0.89 [0.82–0.96], p = 0.04). Conclusion: A ROX index greater than 4.88 appears to have a poor ability to predict intubation in immunocompromised patients with acute respiratory failure, although it remains highly associated with the risk of intubation and may be useful to stratify such risk in future studies., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021
4. Ethical climate and intention to leave among critical care clinicians: an observational study in 68 intensive care units across Europe and the United States
- Author
-
Van den Bulcke, B, Metaxa, V, Reyners, AK, Rusinova, K, Jensen, HI, Malmgren, J, Darmon, M, Talmor, D, Meert, AP, Cancelliere, L, Zubek, L, Maia, P, Michalsen, A, Kompanje, Erwin, Vlerick, P, Roels, J, Vansteelandt, S, Decruyenaere, J, Azoulay, E, Vanheule, S, Piers, R, Benoit, D, Van den Bulcke, B, Metaxa, V, Reyners, AK, Rusinova, K, Jensen, HI, Malmgren, J, Darmon, M, Talmor, D, Meert, AP, Cancelliere, L, Zubek, L, Maia, P, Michalsen, A, Kompanje, Erwin, Vlerick, P, Roels, J, Vansteelandt, S, Decruyenaere, J, Azoulay, E, Vanheule, S, Piers, R, and Benoit, D
- Published
- 2020
5. The Jules Bordet Institute, a pioneer in the development of intensive oncology care
- Author
-
Sculier, JP, primary and Meert, AP, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy
- Author
-
Bauer, Pr, Chevret, S, Yadav, H, Mehta, S, Pickkers, P, Bukan, Rb, Rello, J, van de Louw, A, Klouche, K, Meert, Ap, Martin-Loeches, I, Marsh, B, Crespi, Ls, Moreno-Gonzalez, G, Buchtele, N, Amrein, K, Balik, M, Antonelli, Massimo, Nyunga, M, Barratt-Due, A, Bergmans, Dcjj, Spoelstra-de Man, Ame, Kuitunen, A, Wallet, F, Seguin, A, Metaxa, V, Lemiale, V, Burghi, G, Demoule, A, Karvunidis, T, Cotoia, A, Klepstad, P, Moller, Am, Mokart, D, Azoulay, E, Rabbat, A, Darmon, M, Platon, L, Mayaux, J, Chermak, A, Lemaitre, C, Artaud-Macari, E, Nelsen, J, Kaufmann, T, Viana, W, Lishoa, T, Correa, Td, Encina, B, Socias, A, Manez, R, Rodriguez-Ruis, E, Benoit, D, Staudinger, T, Heinz, G, Sengolge, G, Zauner, C, Jaksch, P, Mcmahon, A, Martin, B, Cinnella, G, Shah, S, Hemelaar, P, Taccone, Fs, Salluh, J, Schellongowski, P, Rusinova, K, Terzi, N, Kouatchet, A, Valkonen, M, Bruneel, F, Pene, F, Moreau, As, Girault, C, Silva, Uva, Montini, Luca, Barbier, F, Gaborit, B, Viana, Wn, de Moraes, App, Moralez, Gm, Vinatier, I, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de biostatistiques et information médicale [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPC), University of Toronto, Radboud University Medical Center [Nijmegen], Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III [Madrid] (ISC), Vall d'Hebron University Hospital [Barcelona], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Jules Bordet [Bruxelles], Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Université libre de Bruxelles (ULB), St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Universitat de Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de réanimation médicale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU), Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neurophysiologie Respiratoire Expérimentale et Clinique, Intensive Care, MUMC+: MA Medische Staf IC (9), MUMC+: MA Arts Assistenten IC (9), RS: NUTRIM - R2 - Liver and digestive health, Intensive care medicine, ACS - Atherosclerosis & ischemic syndromes, and ACS - Diabetes & metabolism
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,BRONCHOALVEOLAR LAVAGE ,HEMATOLOGIC MALIGNANCIES ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,All institutes and research themes of the Radboud University Medical Center ,Bronchoscopy ,law ,Settore MED/41 - ANESTESIOLOGIA ,Severity of illness ,FLEXIBLE BRONCHOSCOPY ,medicine ,030212 general & internal medicine ,Prospective cohort study ,UTILITY ,medicine.diagnostic_test ,business.industry ,GROUPE ,Diagnosis outcome acute respiratory failure immunocompromised patients ,Intensive care unit ,3. Good health ,ONCOLOGY PATIENTS ,Bronchoalveolar lavage ,YIELD ,030228 respiratory system ,Respiratory failure ,INFECTIONS ,SAFETY ,Propensity score matching ,Emergency medicine ,Observational study ,Pneumologie ,business - Abstract
OBJECTIVE: We wished to explore the use, diagnostic capability and outcomes of bronchoscopy added to noninvasive testing in immunocompromised patients. In this setting, an inability to identify the cause of acute hypoxaemic respiratory failure is associated with worse outcome. Every effort should be made to obtain a diagnosis, either with noninvasive testing alone or combined with bronchoscopy. However, our understanding of the risks and benefits of bronchoscopy remains uncertain. PATIENTS AND METHODS: This was a pre-planned secondary analysis of Efraim, a prospective, multinational, observational study of 1611 immunocompromised patients with acute respiratory failure admitted to the intensive care unit (ICU). We compared patients with noninvasive testing only to those who had also received bronchoscopy by bivariate analysis and after propensity score matching. RESULTS: Bronchoscopy was performed in 618 (39%) patients who were more likely to have haematological malignancy and a higher severity of illness score. Bronchoscopy alone achieved a diagnosis in 165 patients (27% adjusted diagnostic yield). Bronchoscopy resulted in a management change in 236 patients (38% therapeutic yield). Bronchoscopy was associated with worsening of respiratory status in 69 (11%) patients. Bronchoscopy was associated with higher ICU (40% versus 28%; p, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2019
7. Paraneoplastic hypercortisolism : case report and review of available therapeutic options
- Author
-
Nguyen, A, primary, Grigoriu, B, additional, and Meert, AP, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Outcome in patients perceived as receiving excessive care across different ethical climates: a prospective study in 68 intensive care units in Europe and the USA
- Author
-
Benoit, DD, Jensen, HI, Malmgren, J, Metaxa, V, Reyners, AK, Darmon, M, Rusinova, K, Talmor, D, Meert, AP, Cancelliere, L, Zubek, L, Maia, P, Michalsen, A, Vanheule, S, Kompanje, Erwin, Decruyenaere, J, Vandenberghe, S, Vansteelandt, S, Gadeyne, B, Van den Bulcke, B, Azoulay, E, Piers, RD, Benoit, DD, Jensen, HI, Malmgren, J, Metaxa, V, Reyners, AK, Darmon, M, Rusinova, K, Talmor, D, Meert, AP, Cancelliere, L, Zubek, L, Maia, P, Michalsen, A, Vanheule, S, Kompanje, Erwin, Decruyenaere, J, Vandenberghe, S, Vansteelandt, S, Gadeyne, B, Van den Bulcke, B, Azoulay, E, and Piers, RD
- Published
- 2018
9. Elderly patients with cancer in the ICU
- Author
-
Sirjacques, C, primary, Ameye, L, additional, Berghmans, T, additional, Paesmans, M, additional, Sculier, JP, additional, and Meert, AP, additional
- Published
- 2018
- Full Text
- View/download PDF
10. ESICM LIVES 2016: part two : Milan, Italy. 1-5 October 2016
- Author
-
Sivakumar, S, Taccone, FS, Desai, KA, Lazaridis, C, Skarzynski, M, Sekhon, M, Henderson, W, Griesdale, D, Chapple, L, Deane, A, Williams, L, Ilia, S, Henderson, A, Hugill, K, Howard, P, Roy, A, Bonner, S, Monteiro, E, Baudouin, S, Ramírez, CS, Escalada, SH, Banaszewski, M, Sertedaki, A, Kaymak, Ç, Viera, MA, Santana, MC, Balcázar, LC, Monroy, NS, Campelo, FA, Vázquez, CF, Santana, PS, Cerejo, A, Santana, SR, Charmadari, E, Carteron, L, Kovach, L, Patet, C, Quintard, H, Solari, D, Bouzat, P, Oddo, M, Wollersheim, T, Malleike, J, Haas, K, Stratakis, CA, Rocha, AP, Carbon, N, Şencan, I, Schneider, J, Birchmeier, C, Fielitz, J, Spuler, S, Weber-Carstens, S, Enseñat, L, Pérez-Madrigal, A, Briassouli, E, Saludes, P, Proença, L, Elsayed, AA, Meço, B, Gruartmoner, G, Espinal, C, Mesquida, J, Huber, W, Eckmann, M, Elkmann, F, Goukos, D, Gruber, A, Lahmer, T, Mayr, U, Herner, A, Özçelik, M, Abougabal, AM, Schellnegger, R, Schmid, RM, Ayoub, W, Psarra, K, Samy, W, Esmat, A, Battah, A, Mukhtar, S, Mongkolpun, W, Ünal, N, Cortés, DO, Beshey, BN, Cordeiro, CP, Vincent, JL, Leite, MA, Creteur, J, Funcke, S, Groesdonk, H, Saugel, B, Wagenpfeil, G, Wagenpfeil, S, Reuter, DA, Fernandez, MM, Alzahaby, KM, Botoula, E, Fernandez, R, Magret, M, González-Castro, A, Bouza, MT, Ibañez, M, García, C, Balerdi, B, Jenni-Moser, B, Mas, A, Arauzo, V, Tsagarakis, S, Añón, JM, Pozzebon, S, Ruiz, F, Ferreres, J, Tomás, R, Alabert, M, Tizón, AI, Altaba, S, Jeitziner, MM, Llamas, N, Haroon, BA, Edul, VS, Goligher, EC, Fan, E, Herridge, M, Ortiz, AB, Vorona, S, Sklar, M, Dres, M, Rittayamai, N, Lanys, A, Schreiber, J, Mageira, E, Urrea, C, Tomlinson, G, Reid, WD, Rubenfeld, GD, Kavanagh, BP, Cristallini, S, Brochard, LJ, Ferguson, ND, Neto, AS, De Abreu, MG, Routsi, C, Imiela, J, Galassi, MS, Pelosi, P, Schultz, MJ, PRoVENT investigators and the PROVE Network, Guérin, C, Papazian, L, Reignier, J, Lheureux, O, Ayzac, L, Nanas, S, Loundou, A, Forel, JM, Sales, FL, Rolland-Debord, C, Bureau, C, Poitou, T, Clavel, M, Perbet, S, Terzi, N, Kouatchet, A, Briassoulis, G, Brasseur, A, Similowski, T, Demoule, A, De Moraes, KC, Hunfeld, N, Trogrlic, Z, Ladage, S, Osse, RJ, Koch, B, Rietdijk, W, Boscolo, A, Devlin, J, Van der Jagt, M, Picetti, E, Batista, CL, Ceccarelli, P, Mensi, F, Malchiodi, L, Risolo, S, Rossi, I, Bertini, D, Antonini, MV, Servadei, F, Caspani, ML, Roquilly, A, Júnior, JA, Lasocki, S, Seguin, P, Geeraerts, T, Perrigault, PF, Campello, E, Dahyot-Fizelier, C, Paugam-Burtz, C, Cook, F, Cinotti, R, Dit Latte, DD, Mahe, PJ, Marcari, TB, Fortuit, C, Feuillet, F, Lucchetta, V, Asehnoune, K, Marzorati, C, Spina, S, Scaravilli, V, Vargiolu, A, Riva, M, Giussani, C, Lobato, R, Sganzerla, E, Hravnak, M, Osaku, EF, Citerio, G, Barbadillo, S, De Molina, FJ, Álvarez-Lerma, F, Rodríguez, A, SEMICYUC/GETGAG Working Group, Zakharkina, T, Martin-Loeches, I, Castro, CS, Matamoros, S, Fuhrmann, V, Piasentini, E, Povoa, P, Yousef, K, Torres, A, Kastelijn, J, Hofstra, JJ, De Jong, M, Schultz, M, Sterk, P, Artigas, A, De Souza, LM, Aktepe, O, Bos, LJ, Moreau, AS, Chang, Y, Salluh, J, Rodriguez, A, Nseir, S, TAVeM study group, De Jong, E, Fildisis, G, Rodrigues, FF, Van Oers, JA, Beishuizen, A, Girbes, AR, Nijsten, MW, Crago, E, De Lange, DW, Bonvicini, D, Labate, D, Benacchio, L, Radu, CM, Olivieri, A, Stepinska, J, Wruck, ML, Pizzirani, E, Lopez-Delgado, JC, Gonzalez-Romero, M, Fuentes-Mila, V, Berbel-Franco, D, Friedlander, RM, Romera-Peregrina, I, Manesso, L, Martinez-Pascual, A, Perez-Sanchez, J, Abellan-Lencina, R, Correa, NG, Ávila-Espinoza, RE, Moreno-Gonzalez, G, Sbraga, F, Griffiths, S, Grocott, MP, Creagh-Brown, B, Simioni, P, Abdelmonem, SA, POPC-CB investigators, Doyle, J, Wilkerson, P, Pelegrini, AM, Soon, Y, Huddart, S, Dickinson, M, Riga, A, Zuleika, A, Ori, C, Miyamoto, K, Kawazoe, Y, Tahon, SA, Morimoto, T, Yamamoto, T, Eid, RA, Fuke, A, Hashimoto, A, Koami, H, Beppu, S, Su, H, Katayama, Y, Ito, M, Ohta, Y, Yamamura, H, Helmy, TA, DESIRE (DExmedetomidine for Sepsis in ICU Randomized Evaluation) Trial Investigators, Timenetsky, KT, Rygård, SL, Holst, LB, Wetterslev, J, Lam, YM, Johansson, PI, Perner, A, Soliman, IW, Van Dijk, D, Van Delden, JJ, Meligy, HS, Cazati, D, Cremer, OL, Slooter, AJ, Willis, K, Peelen, LM, McWilliams, D, Snelson, C, Neves, AD, Loudet, CI, Busico, M, Vazquez, D, Villalba, D, Lobato, M, Puig, F, Kott, M, Pullar, V, Veronesi, M, Lischinsky, A, López, FJ, Mori, LB, Plotnikow, G, Díaz, A, Giannasi, S, Hernandez, R, Krzisnik, L, Diniz, PS, Hubner, RP, Cecotti, C, Dunn-Siegrist, I, Viola, L, Lopez, R, Sottile, JP, Benavent, G, Estenssoro, E, Chen, CM, Lai, CC, Cheng, KC, Costa, CR, Rocha, LL, Chou, W, Chan, KS, Pugin, J, Roeker, LE, Horkan, CM, Gibbons, FK, Christopher, KB, Weijs, PJ, Mogensen, KM, Furche, M, Rawn, JD, Cavalheiro, AM, Robinson, MK, Tang, Z, Gupta, S, Qiu, C, Ouyang, B, Cai, C, Guan, X, Tsang, JL, Regueira, T, Cea, L, Topeli, A, Lucinio, NM, Carlos, SJ, Elisa, B, Puebla, C, Vargas, A, Govil, D, Poulsen, MK, De Guadiana-Romualdo, LG, Thomsen, LP, Kjærgaard, S, Rees, SE, Karbing, DS, Schwedhelm, E, Frank, S, Müller, MC, Carbon, NM, Skrypnikov, V, Rebollo-Acebes, S, Srinivasan, S, Pickerodt, PA, Falk, R, Mahlau, A, Santos, ER, Lee, A, Inglis, R, Morgan, R, Barker, G, Esteban-Torrella, P, Kamata, K, Abe, T, Patel, SJ, Saitoh, D, Tokuda, Y, Green, RS, Norrenberg, M, Butler, MB, Erdogan, M, Hwa, HT, Jiménez-Sánchez, R, Gil, LJ, Vaquero, RH, Rodriguez-Ruiz, E, Lago, AL, N, JK, Allut, JL, Gestal, AE, Gleize, A, Gonzalez, MA, Thomas-Rüddel, DO, Jiménez-Santos, E, Schwarzkopf, D, Fleischmann, C, Reinhart, K, Suwanpasu, S, Sattayasomboon, Y, Filho, NM, Gupta, A, Oliveira, JC, Preiser, JC, Ballalai, CS, Zitta, K, Ortín-Freire, A, De Lucia, CV, Araponga, GP, Veiga, LN, Silva, CS, Garrido, ME, Ramos, BB, Ricaldi, EF, Gomes, SS, Tomar, DS, Simón, IF, Hernando-Holgado, A, GEMINI, Gemmell, L, MacKay, A, Wright, C, Docking, RI, Doherty, P, Black, E, Stenhouse, P, Plummer, MP, Finnis, ME, Albaladejo-Otón, MD, Carmona, SA, Shafi, M, Phillips, LK, Kar, P, Bihari, S, Biradar, V, Moodie, S, Horowitz, M, Shaw, JE, Deane, AM, Coelho, L, Yatabe, T, Valhonrat, IL, Inoue, S, Harne, R, Sakaguchi, M, Egi, M, Abdelhamid, YA, Motta, MF, Domínguez, JP, Arora, DP, Hokka, M, Pattinson, KT, Mizobuchi, S, Pérez, AG, Abellán, AN, Plummer, M, Giersch, E, Talwar, N, Summers, M, Pelenz, M, Hatzinikolas, S, Heller, S, Chapman, M, Jones, K, Almudévar, PM, Schweizer, R, Jacquet-Lagreze, M, Portran, P, Rabello, L, Mazumdar, S, Junot, S, Allaouchiche, B, Fellahi, JL, Guerci, P, Ergin, B, Lange, K, Kapucu, A, Ince, C, Cioccari, L, Luethi, N, Crisman, M, Papakrivou, EE, Bellomo, R, Mårtensson, J, Shinotsuka, CR, Fagnoul, D, Kluge, S, Orbegozo, D, Makris, D, Thooft, A, Brimioulle, S, Dávila, F, Iwasaka, H, Brandt, B, Tahara, S, Nagamine, M, Ichigatani, A, Cabrera, AR, Zepeda, EM, Granillo, JF, Manoulakas, E, Sánchez, JS, Montoya, AA, Rubio, JJ, Montenegro, AP, Blanco, GA, Robles, CM, Drolz, A, Horvatits, T, Roedl, K, Rutter, K, Tsolaki, B, Funk, GC, Póvoa, P, Ramos, AJ, Schneeweiss, B, Sabetian, G, Pooresmaeel, F, Zand, F, Ghaffaripour, S, Farbod, A, Tabei, H, Taheri, L, TAVeM study Group, Karadodas, B, Reina, Á, Anandanadesan, R, Metaxa, V, Teixeira, C, Pereira, SM, Hernández-Marrero, P, Carvalho, AS, Beckmann, M, Hartog, CS, Varis, E, Raadts, A, López, NP, Zakynthinos, E, Robertsen, A, Førde, R, Skaga, NO, Helseth, E, Honeybul, S, Ho, K, Vazquez, AR, Lopez, PM, Gonzalez, MN, Ortega, PN, Pérez, MA, Sola, EC, Garcia, IP, Spasova, T, De la Torre-Prados, MV, Kopecky, O, Rusinova, K, Pettilä, V, Waldauf, P, Cepeplikova, Z, Balik, M, Ordoñez, PF, Apolo, DX, Almudevar, PM, Martin, AD, Muñoz, JJ, Poukkanen, M, Castañeda, DP, Villamizar, PR, Ramos, JV, Pérez, LP, Lucendo, AP, Villén, LM, Ejarque, MC, Estella, A, Camps, VL, Neitzke, NM, Encinares, VS, Martín, MC, Masnou, N, Bioethics work group of SEMICYUC, Barbosa, S, Varela, A, Palma, I, López, FM, Cristina, L, Nunes, E, Jacob, S, Pereira, I, Campello, G, Ibañez, MP, Granja, C, Pande, R, Pandey, M, Varghese, S, Chanu, M, García, IP, Van Dam, MJ, Schildhauer, C, Karlsson, S, Ter Braak, EW, Gracia, M, Viciana, R, Montero, JG, Recuerda, M, Fontaiña, LP, Tharmalingam, B, Kovari, F, Zöllner, C, Rose, L, Mcginlay, M, Amin, R, Burns, K, Connolly, B, Hart, N, Labrador, G, Jouvet, P, Katz, S, Leasa, D, Takala, J, Izurieta, JR, Mawdsley, C, Mcauley, D, Blackwood, B, Denham, S, Worrall, R, Arshad, M, Cangueiro, TC, Isherwood, P, Wilkman, E, Khadjibaev, A, Guerrero, JJ, Sabirov, D, Rosstalnaya, A, Parpibaev, F, Sharipova, V, Guzman, CI, FINNAKI Study Group, Poulose, V, Renal Transplantation HUVR, Lundberg, OH, Koh, J, Calvert, S, Cha, YS, Lee, SJ, Tyagi, N, Rajput, RK, Birri, PN, Taneja, S, Singh, VK, Sharma, SC, Mittal, S, Quint, M, Kam, JW, Rao, BK, Ayachi, J, Fraj, N, Romdhani, S, Bergenzaun, L, Khedher, A, Meddeb, K, Sma, N, Azouzi, A, Bouneb, R, Giribet, A, Adeniji, K, Chouchene, I, Yeter, H, El Ghardallou, M, Rydén, J, Boussarsar, M, Jennings, R, Walter, E, Ribeiro, JM, Moniz, I, Marçal, R, Santos, AC, Young, R, Candeias, C, E Silva, ZC, Rosenqvist, M, Kara, A, Gomez, SE, Nieto, OR, Gonzalez, JA, Cuellar, AI, Mildh, H, Korhonen, AM, Shevill, DD, Elke, G, Moraes, MM, Ala-Kokko, T, Reinikainen, M, Robertson, E, Garside, P, Tavladaki, T, Isotti, P, De Vecchi, MM, Perduca, AE, Cuervo, MA, Melander, O, Negro, A, Villa, G, Manara, DF, Cabrini, L, Zangrillo, A, Frencken, JF, Spanaki, AM, Van Baal, L, Donker, DW, Chew, MS, Cuervo, RA, Horn, J, Van der Poll, T, Van Klei, WA, Bonten, MJ, Menard, CE, Kumar, A, Dimitriou, H, Rimmer, E, Doucette, S, Esteban, MA, Turgeon, AF, Houston, BL, Houston, DS, Zarychanski, R, Pinto, BB, Carrara, M, Ferrario, M, Bendjelid, K, Kondili, E, Nunes, J, Fraile, LI, Diaz, P, Silva, G, Escórcio, S, Chaves, S, Jardim, M, Fernandes, N, Câmara, M, Duarte, R, Pereira, CA, Choulaki, C, Mittelbrum, CP, Vieira, J, Nóbrega, JJ, De Oca-Sandoval, MA, Sánchez-Rodríguez, A, Joya-Galeana, JG, Correa-Morales, A, Camarena-Alejo, G, Aguirre-Sánchez, J, Franco-Granillo, J, Albaiceta, GM, Meleti, E, Soliman, M, Al Azab, A, El Hossainy, R, Nagy, H, Nirmalan, M, Crippa, IA, Cavicchi, FZ, Koeze, J, Kafetzopoulos, D, Chaari, A, Hakim, KA, Hassanein, H, Etman, M, El Bahr, M, Bousselmi, K, Khalil, ES, Kauts, V, Tsolakoglou, I, Casey, WF, Imahase, H, Georgopoulos, D, Sakamoto, Y, Yamada, KC, Miike, T, Nagashima, F, Iwamura, T, Keus, F, Hummitzsch, L, Kishihara, Y, Heyland, D, Spiezia, L, Dieperink, W, Souza, RB, Yasuda, H, Martins, AM, Liberatore, AM, Kang, YR, Nakamae, MN, La Torre, AG, Vieira, JC, Koh, IH, Hanslin, K, Wilske, F, Van der Horst, IC, Jaskowiak, JL, Skorup, P, Sjölin, J, Lipcsey, M, Long, WJ, Zhen, CE, Vakalos, A, Avramidis, V, Wu, SH, Shyu, LJ, Rebollo, S, Van Meurs, M, Li, CH, Yu, CH, Chen, HC, Wang, CH, Lin, KH, Aray, ZE, Gómez, CF, Tsvetanova-Spasova, T, Tejero, AP, Monge, DD, Zijlstra, JG, Losada, VM, Tarancón, CM, Cortés, SD, Gutiérrez, AM, Álvarez, TP, Rouze, A, Jaffal, K, Six, S, Jimenez, R, Nuevo-Ortega, P, Stolz, K, Roberts, S, Cattoen, V, Arnal, JM, Saoli, M, Novotni, D, Garnero, A, Becher, T, Torrella, PE, Buchholz, V, Schädler, D, Rueda-Molina, C, Caballero, CH, Frerichs, I, Weiler, N, Eronia, N, Mauri, T, Gatti, S, Maffezzini, E, Fernandez, A, Bronco, A, Alban, L, Sasso, T, Marenghi, C, Isgro, G, Fernández-Porcel, A, Grasselli, G, Pesenti, A, Bellani, G, Al-Fares, A, Dubin, A, Del Sorbo, L, Anwar, S, Facchin, F, Azad, S, Zamel, R, Hall, D, Ferguson, N, Camara-Sola, E, Cypel, M, Keshavjee, S, Sanchez, S, Durlinger, E, Spoelstra-de Man, A, Smit, B, De Grooth, HJ, Girbes, A, Beitland, S, Straaten, HO, Smulders, Y, Salido-Díaz, L, Ortin, A, Alfaro, MA, Parrilla, F, Meli, A, Pellegrini, M, Rodriguez, N, Goyeneche, JM, Morán, I, Intas, G, Aguirre, H, Mancebo, J, Bassi, GL, Heines, SJ, García-Alcántara, A, Strauch, U, Bergmans, DC, Blankman, P, Shono, A, Hasan, D, Gommers, D, Trøseid, AM, Chung, WY, Prats, RG, Lee, KS, Jung, YJ, Park, JH, Sheen, SS, Park, KJ, Worral, R, Brusletto, BS, Larraza, S, Dey, N, Spadaro, S, Brohus, JB, Winding, RW, Volta, CA, Silva, MM, Waldum-Grevbo, BE, Ampatzidou, F, Vlachou, A, Kehagioglou, G, Karaiskos, T, Madesis, A, Mauromanolis, C, Michail, N, Drossos, G, Aguilera, E, Saraj, N, Berg, JP, Rijkenberg, S, Feijen, HM, Endeman, H, Donnelly, AA, Morgan, E, Garrard, H, Buckley, H, Russell, L, Marti, D, Haase, N, Sunde, K, Goh, C, Mouyis, K, Woodward, CL, Halliday, J, Encina, GB, Ros, J, Ranzani, OT, Lagunes, L, Tabernero, J, Huertas, DG, Bosch, F, Rello, J, Manzano, F, Morente-Constantin, E, Rivera-Ginés, B, Rigol, M, Colmenero-Ruiz, M, Meleti, DE, Sanz, JG, Dogliotti, A, Simon, IF, Valbuena, BL, Pais, M, Ramalingam, S, Quintana, MM, Díaz, C, Fox, L, Santafe, M, Fernandez, L, Barba, P, García, M, Leal, S, Pérez, M, Pérez, ML, Osuna, A, Ferrer, M, Veganzones, J, Martínez, N, Santiago-Ruiz, F, Moors, I, Mokart, D, Pène, F, Lambert, J, Mayaux, J, Vincent, F, Nyunga, M, Bruneel, F, Stergiannis, P, Laisne, L, Rabbat, A, Lebert, C, Perez, P, Suberviola, B, Chaize, M, Renault, A, Meert, AP, Hamidfar, R, Jourdain, M, Rodríguez-Mejías, C, Lanziotti, VS, Darmon, M, Schlemmer, B, Chevret, S, Lemiale, V, Azoulay, E, Rowland, MJ, Riera, J, Benoit, D, Martins-Branco, D, Sousa, M, Wangensteen, R, Marum, S, Bouw, MJ, Galstyan, G, Makarova, P, Parovichnikova, E, Kuzmina, L, Troitskaya, V, Rellan, L, Drize, N, Zaponi, RS, Gemdzhian, E, Jamaati, HR, Savchenko, V, Chao, HC, Kılıc, E, Demiriz, B, Uygur, ML, Sürücü, M, Cınar, K, Yıldırım, AE, Pulcheri, L, Sanchez, M, Kiss, K, Masjedi, M, Köves, B, Csernus, V, Molnár, Z, Ntantana, A, Matamis, D, Savvidou, S, Giannakou, M, Ribeiro, MO, Gouva, M, Nakos, G, Robles, JC, Koulouras, V, Gaffney, S, Docking, R, Judge, C, Drew, T, Barbosa, AP, Misran, H, Munshi, R, McGovern, L, Coyle, M, Hashemian, SM, Lopez, E, Dunne, L, Deasy, E, Lavin, P, Fahy, A, Antoniades, CA, Ramos, A, Darcy, DM, Donnelly, M, Ismail, NH, Hall, T, Wykes, K, Jack, J, Vicente, R, Ngu, WC, Morgan, P, E Silva, JR, Ruiz-Ramos, J, Ramirez, P, Gordon, M, Villarreal, E, Frasquet, J, Poveda-Andrés, JL, Abbasi, G, Castellanos, A, Ijssennagger, CE, Miñambres, E, Soares, M, Ten Hoorn, S, Van Wijk, A, Van den Broek, JM, Tuinman, PR, Elmenshawy, AM, Hammond, BD, Gibbon, G, Khaloo, V, Belcham, T, Burton, K, Salluh, JI, Taniguchi, LU, Santibañez, M, Ramos, FJ, Momma, AK, Martins-Filho, AP, Bartocci, JJ, Lopes, MF, Sad, MH, Tabei, SH, Rodrigues, CM, Pires, EM, Vieira, JM, Le Guen, M, Murbach, LD, Barreto, J, Duarte, ST, Taba, S, Kolaros, AA, Miglioranza, D, Gund, DP, Lordani, CF, Ogasawara, SM, Moore, J, Jorge, AC, Duarte, PA, Capuzzo, M, Marqués, MG, Kafilzadeh, A, Corte, FD, Terranova, S, Scaramuzzo, G, Fogagnolo, A, Bertacchini, S, Bellonzi, A, Garry, P, Mason, N, Ragazzi, R, Moreno, AP, Bakhodaei, HH, Cruz, C, Nunes, A, Pereira, FS, Aragão, I, Cardoso, AF, Santos, C, Malheiro, MJ, Castro, H, Abentroth, LR, Windpassinger, M, Cardoso, T, Diaz, JA, Paratz, J, Kenardy, J, Comans, T, Coyer, F, Thomas, P, Boots, R, Pereira, N, Pizarraya, AG, Vilas-Boas, A, Gomes, E, Plattner, O, Silva, R, Dias, C, Torres, J, Carvalho, D, Molinos, E, Vales, C, Araújo, R, Witter, T, Diaz, JP, Garcia, DJ, Mascha, E, Lovesio, C, Karnatovskaia, L, Philbrick, K, Ognjen, G, Clark, M, Montero, RM, Luis, E, Varas, JL, Sessler, DI, Sánchez-Elvira, LA, Delgado, CP, Díaz, PV, Ruiz, BL, Guerrero, AP, Galache, JA, Jiménez, R, Gomez, MN, Alejandro, O, Fernández, A, Research, O, Smani, Y, Moreno, S, Herrera, L, Ojados, A, Galindo, M, Murcia, J, Contreras, M, Sánchez-Argente, S, Soriano, R, Bonilla, Y, Rodríguez, MD, Connell, MM, Allegue, JM, Melia, U, Cakin, Ö, Parlak, H, Kirca, H, Mutlu, F, Aydınlı, B, Cengiz, M, Gonzalez, PL, Ramazanoglu, A, Zhang, LA, Jung, EJ, Oh, SY, Lee, H, Fontanet, J, Ibrahim, IA, Parker, RS, Van den Berg, JP, Domenech, JC, Montalvo, AP, Banerjee, I, Chalari, E, Chornet, TC, Martinez, PC, Ribas, MP, Costa, RG, Ortega, AC, Forbes, C, Struys, MM, Prescott, H, Lal, A, Clermont, G, Khan, FA, Rafik, MM, Dela Pena, EG, Dizon, JS, Perez, PP, Wong, CM, Garach, MM, Romero, OM, Puerta, RR, Westbrook, J, Norberg, E, Vereecke, HE, Diaz, FA, Al-Ansary, AM, Bailon, AM, Pinel, AC, Maldonado, LP, Kalaiselvan, MS, Kumar, RL, Renuka, MK, Kumar, AS, Myatra, SN, De Rosa, S, Ferrari, F, Jensen, EW, Algendi, MA, Checcacci, SC, Rigobello, A, Joannidis, M, Politi, F, Pellizzari, A, Bonato, R, Oras, J, Fernandez-Carmona, A, Macias-Guarasa, I, Gutierrez-Rodriguez, R, Martinez-Lopez, P, Ali, AA, Rood, PJ, Diaz-Castellanos, MA, EDISVAL Group, Arias-Diaz, M, Vaara, ST, Aguilar-Alonso, E, Nikandish, RN, Van de Schoor, F, Artemenko, V, Budnyuk, A, Delile, E, Senussi, T, Idone, F, Xiol, EA, Travierso, C, Chiurazzi, C, Motos, A, Amaro, R, Van Tertholen, K, Cuisinier, A, Hua, Y, Fernández-Barat, L, Bobi, Q, Youn, A, Hwang, JG, Maufrais, C, Pickkers, P, Ossorio, ME, Figueira, H, Payen, JF, Oliveira, R, Mota, A, Van den Boogaard, M, Kamp, O, Cruciger, O, Aach, M, Kaczmarek, C, Waydhas, C, Nottin, S, Schildhauer, TA, Hamsen, U, Camprubí-Rimblas, M, Chimenti, L, Guillamat-Prats, R, Beardow, ZJ, Lebouvier, T, Bringué, J, Tijero, J, Gómez, MN, Walther, G, Benten, D, Blanch, L, Tagliabue, G, Ji, M, Jagers, JV, Easton, PA, Redhead, H, Athanasiadou, E, Hong, JY, Shin, MH, Park, MS, Paramasivam, K, Albrecht, M, Arib, S, Pomprapa, A, Kluwe, J, Hofferberth, MB, Russ, M, Braun, W, Walter, M, Francis, R, Lachmann, B, Leonhardt, S, Bilotta, F, Corkill, R, Numan, T, Siedler, S, Landaverde-López, A, Canedo-Castillo, NA, Badenes, R, Esquivel-Chávez, A, Arvizu-Tachiquín, PC, Sánchez-Hurtado, LA, Baltazar-Torres, JA, Cardoso, V, Krystopchuk, A, Castro, S, Melão, L, Firmino, S, Marreiros, A, Almaziad, S, Kubbara, A, Adedugbe, I, Barnett, W, Kamper, AM, Nakity, R, Alamoudi, W, Strickland, R, Altook, R, Tarazi, T, Fida, M, Safi, F, Assaly, R, Santini, A, Bird, GT, Milesi, M, Maraffi, T, Rood, P, Rubulotta, F, Pugni, P, Andreis, DT, Cavenago, M, Gattinoni, L, Protti, A, Perchiazzi, G, Borges, JB, Queen Square Neuroanaesthesia and Neurocritical Care Resreach Group, Bayat, S, Porra, L, Mirek, S, Broche, L, Hedenstierna, G, Larsson, A, Kennedy, RM, Roneus, A, Segelsjö, M, Vestito, MC, Zeman, PM, Gremo, E, Nyberg, A, Castegren, M, Pikwer, A, Sharma, S, Monfort, B, Yoshida, T, Engelberts, D, Otulakowski, G, Katira, B, Post, M, Brochard, L, Amato, MB, Stazi, E, PLUG Working group, Koch, N, Hoellthaler, J, Mair, S, Phillip, V, Van Ewijk, CE, Beitz, A, González, LR, Roig, AL, Baladrón, V, Yugi, G, Calvo, FJ, Padilla, D, Villarejo, P, Villazala, R, Yuste, AS, Bejarano, N, Steenstra, RJ, Jacobs, GE, Banierink, H, Hof, J, Martika, A, Hoekstra, M, Sterz, F, Horvatits, K, Herkner, H, Magnoni, S, Marando, M, Faivre, V, Pifferi, S, Conte, V, Ortolano, F, Alonso, DC, Carbonara, M, Bertani, G, Scola, E, Cadioli, M, Triulzi, F, Colombo, A, Nevière, R, Stocchetti, N, Fatania, G, Hernández-Sánchez, N, Rotzel, HB, Lázaro, AS, Prada, DA, Guimillo, MR, Piqueras, CS, Guia, JR, Simon, MG, Thiébaut, PA, Arizmendi, AM, Carratalá, A, Sánchez, RDEP, El Maraghi, S, Yehia, A, Bakry, M, Shoman, A, Backes, FN, Bianchin, MM, Vieira, SR, Maupoint, J, De Souza, A, Lucas, JH, Backes, AN, Klein, C, García-Guillen, FJ, Arunkumar, AS, Lozano, A, Mulder, P, Gallaher, C, Cattlin, S, Ñamendys-Silva, SA, Gordon, S, Picard, J, Fontana, V, Bond, O, Coquerel, D, Nobile, L, Mrozek, S, Delamarre, L, Maghsoudi, B, Capilla, F, Al-Saati, T, Fourcade, O, Renet, S, Dominguez-Berrot, AM, Gonzalez-Vaquero, M, Vallejo-Pascual, ME, Gupta, D, Ivory, BD, Chopra, M, Emami, M, Khaliq, W, McCarthy, J, Felderhof, CL, Do Rego, JC, MacNeil, C, Maggiorini, M, Duska, F, Department of Professional Development, ESICM, Fumis, RR, Junior, JM, Khosravi, MB, Amarante, G, Rieusset, J, Skorko, A, Sanders, S, Aron, J, Kroll, RJ, Redfearn, C, Harish, MM, Krishnan, P, Khalil, JE, Kongpolprom, N, Richard, V, Gulia, V, Lourenço, E, Duro, C, Baptista, G, Alves, A, Arminda, B, Rodrigues, M, Tamion, F, Tabatabaie, HR, Hayward, J, Baldwin, F, Gray, R, Katinakis, PA, Stijf, M, Ten Kleij, M, Jansen-Frederiks, M, Broek, R, De Bruijne, M, Mengelle, C, Spronk, PE, Sinha, K, Luney, M, Palmer, K, Keating, L, Abu-Habsa, M, Bahl, R, Baskaralingam, N, Ahmad, A, Kanapeckaite, L, Bhatti, P, Strong, AJ, Sabetiyan, G, Glace, S, Jeyabraba, S, Lewis, HF, Kostopoulos, A, Raja, M, West, A, Ely, A, Turkoglu, LM, Zolfaghari, P, Baptista, JP, Mokri, A, Marques, MP, Martins, P, Pimentel, J, Su, YC, Singer, M, Villacres, S, Stone, ME, Parsikia, A, Medar, S, O'Dea, KP, Nurses of the Central and General ICUs of Shiraz Namazi Hospital, Porter, J, Tirlapur, N, Jonathan, JM, Singh, S, Takata, M, Critical Care Research Group, McWhirter, E, Lyon, R, Troubleyn, J, Hariz, ML, Ferlitsch, A, Azmi, E, Alkhan, J, Smulders, YM, Movsisyan, V, Petrikov, S, Marutyan, Z, Aliev, I, Evdokimov, A, Antonucci, E, Diltoer, M, Merz, T, Hartmann, C, De Waard, MC, Calzia, E, Radermacher, P, Nußbaum, B, Huber-Lang, M, Fauler, G, Gröger, M, Jacobs, R, Zaleska-Kociecka, M, Van Straaten, HM, Trauner, M, Svoren-Jabalera, E, Davenport, EE, Humburg, P, Nguyen, DN, Knight, J, Hinds, CJ, Jun, IJ, Prabu, NR, Kim, WJ, Lee, EH, Besch, G, Perrotti, A, Puyraveau, M, Baltres, M, Eringa, EC, De Waele, E, Samain, E, Chocron, S, Pili-Floury, S, Plata-Menchaca, EP, Sabater-Riera, J, Estruch, M, Boza, E, Toscana-Fernández, J, Man, AM, Bruguera-Pellicer, E, De Regt, J, Ordoñez-Llanos, J, Pérez-Fernández, XL, SIRAKI group, Cavaleiro, P, Tralhão, A, Arrigo, M, Lopes, JP, Lebrun, M, Favier, B, Pischke, S, Cholley, B, PerezVela, JL, Honoré, PM, MarinMateos, H, Rivera, JJ, Llorente, MA, De Marcos, BG, Fernandez, FJ, Laborda, CG, Zamora, DF, Fischer, L, Alegría, L, Grupo ESBAGA, Delgado, JC, Imperiali, C, Myers, RB, Van Gorp, V, Dastis, M, Thaiss, F, Soto, D, Górka, J, Spapen, HD, Górka, K, Iwaniec, T, Koch, M, Frołow, M, Polok, K, Luengo, C, Fronczek, J, Kózka, M, Musiał, J, Szczeklik, W, Contreras, RS, Bangert, K, Gomez, J, Sileli, M, Havaldar, AA, Toapanta, ND, Jarufe, N, Moursia, C, Maleoglou, H, Leleki, K, Uz, Z, Ince, Y, Papatella, R, Bulent, E, Moreno, G, Grabowski, M, Bruhn, A, De Mol, B, Vicka, V, Gineityte, D, Ringaitiene, D, Norkiene, I, Sipylaite, J, Möller, C, Sabater, J, Castro, R, Thomas-Rueddel, DO, Vlasakov, V, Lohse, AW, Rochwerg, B, Theurer, P, Al Sibai, JZ, Camblor, PM, Kattan, E, Torrado, H, Siddiqui, S, Fernandez, PA, Gala, JM, Guisasola, JS, Tamura, T, Miyajima, I, Yamashita, K, Yokoyama, M, Tapia, P, Nashan, B, Gonzalez, M, Dalampini, E, Nastou, M, Baddour, A, Ignatiadis, A, Asteri, T, Hathorn, KE, Sterneck, M, Rebolledo, R, Purtle, SW, Marin, M, Viana, MV, Tonietto, TA, Gross, LA, Costa, VL, Faenza, S, Tavares, AL, Payen, D, Lisboa, BO, Moraes, RB, Farigola, E, Viana, LV, Azevedo, MJ, Ceniccola, GD, Pequeno, RS, Siniscalchi, A, Holanda, TP, Mendonça, VS, Achurra, P, Araújo, WM, Carvalho, LS, Segaran, E, Vickers, L, Gonzalez, A, Brinchmann, K, Pierucci, E, Wignall, I, De Brito-Ashurst, I, Ospina-Tascón, G, Del Olmo, R, Esteban, MJ, Vaquerizo, C, Carreño, R, Gálvez, V, Kaminsky, G, Mancini, E, Fernandez, J, Nieto, B, Fuentes, M, De la Torre, MA, Bakker, J, Torres, E, Alonso, A, Velayos, C, Saldaña, T, Escribá, A, Krishna, B, Grip, J, Kölegård, R, Vera, A, Sundblad, P, Rooyackers, O, Hernández, G, Naser, B, Jaziri, F, Jazia, AB, Barghouth, M, Ricci, D, Hentati, O, Skouri, W, El Euch, M, Mahfoudhi, M, Gisbert, X, Turki, S, Dąbrowski, M, Bertini, P, Abdelghni, KB, Abdallah, B, Gemelli, C, Maha, BN, Cánovas, J, Sotos, F, López, A, Lorente, M, Burruezo, A, Torres, D, Juliá, C, Guarracino, F, Cuoghi, A, Włudarczyk, A, Hałek, A, Bargouth, M, Bennasr, M, Baldassarri, R, Magnani, S, Uya, J, Abdelghani, KB, Abdallah, TB, Geenen, IL, Parienti, JJ, Straaten, HM, Shum, HP, King, HS, Kulkarni, AP, Pinsky, MR, Chan, KC, Corral, L, Yan, WW, Londoño, JG, Cardenas, CL, Pedrosa, MM, Gubianas, CM, Bertolin, CF, Batllori, NV, Atti, M, Sirvent, JM, Sedation an Delirium Group Hospital Universitari de Bellvitge, Mukhopadhyay, A, Chan, HY, Kowitlawakul, Y, Remani, D, Leong, CS, Henry, CJ, Vera, M, Puthucheary, ZA, Mendsaikhan, N, Begzjav, T, Elias-Jones, I, Lundeg, G, Dünser, M, Espinoza, ED, Welsh, SP, Guerra, E, Poppe, A, Zerpa, MC, Zechner, F, Berdaguer, F, Risso-Vazquez, A, Masevicius, FD, Greaney, D, Dreyse, J, Magee, A, Fitzpatrick, G, Lugo-Cob, RG, Jermaine, CM, Tejeda-Huezo, BC, Cano-Oviedo, AA, Carpio, D, Aydogan, MS, Togal, T, Taha, A, Chai, HZ, Sriram, S, Kam, C, Razali, SS, Sivasamy, V, Randall, D, Kuan, LY, Henriquez, C, Morales, MA, Pires, T, Adwaney, A, Wozniak, S, Gajardo, D, Herrera-Gutierrez, ME, Azevedo, LC, Blunden, M, Prowle, JR, Kirwan, CJ, Thomas, N, Martin, A, Owen, H, Darwin, L, Robertson, CS, Bravo, S, Barrueco-Francioni, J, Conway, D, Atkinson, D, Sharman, M, Barbanti, C, Amour, J, Gaudard, P, Rozec, B, Mauriat, P, M'rini, M, Arias-Verdú, D, Rusin, CG, Leger, PL, Cambonie, G, Liet, JM, Girard, C, Laroche, S, Damas, P, Assaf, Z, Loron, G, Lozano-Saez, R, Lecourt, L, Pouard, P, Hofmeijer, J, Kim, SH, Divatia, JV, Na, S, Kim, J, Jung, CW, Sondag, L, Yoo, SH, Min, SH, Chung, EJ, Quesada-Garcia, G, Lee, NJ, Lee, KW, Suh, KS, Ryu, HG, Marshall, DC, Goodson, RJ, Tjepkema-Cloostermans, MC, Salciccioli, JD, Shalhoub, J, Seller-Pérez, G, Potter, EK, Kirk-Bayley, J, Karanjia, ND, Forni, LG, Kim, S, Creagh-Brown, BC, Bossy, M, Nyman, M, Tailor, A, Figueiredo, A, SPACeR group (Surrey Peri-operative, Anaesthesia and Critical Care Collaborative Research Group), D'Antini, D, Valentino, F, Winkler, MS, Sollitto, F, Cinnella, G, Mirabella, L, Anzola, Y, Bosch, FH, Baladron, V, Villajero, P, Lee, M, Redondo, J, Liu, J, Shen, F, Teboul, JL, Anguel, N, Van Putten, MJ, Beurton, A, Bezaz, N, Richard, C, Park, SY, Monnet, X, Fossali, T, Pereira, R, Colombo, R, Ottolina, D, Rossetti, M, Mazzucco, C, Marchi, A, Porta, A, Catena, E, Piotrowska, K, So, S, Bento, L, Tollisen, KH, Andersen, G, Heyerdahl, F, Jacobsen, D, Van IJzendoorn, MC, Buter, H, Kingma, WP, Navis, GJ, Boerma, EC, Rulisek, J, Zacharov, S, Kim, HS, Jeon, SJ, Namgung, H, Lee, E, Lai, M, Kačar, MB, Cho, YJ, Lee, YJ, Huang, A, Deiana, M, Forsberg, M, Edman, G, Kačar, SM, Höjer, J, Forsberg, S, Freile, MT, Hidalgo, FN, Molina, JA, Lecumberri, R, Rosselló, AF, Travieso, PM, Leon, GT, Uddin, I, Sanchez, JG, Ali, MA, Frias, LS, Rosello, DB, Verdejo, JA, Serrano, JA, Winterwerp, D, Van Galen, T, Vazin, A, Karimzade, I, Belhaj, AM, Zand, A, Ozen, E, Ekemen, S, Akcan, A, Sen, E, Yelken, BB, Kureshi, N, Fenerty, L, Thibault-Halman, G, Aydın, MA, Walling, S, Almeida, R, Seller-Perez, G, Clarke, DB, Briassoulis, P, Kalimeris, K, Ntzouvani, A, Nomikos, T, Papaparaskeva, K, Avsec, D, Politi, E, Kostopanagiotou, G, Crewdson, K, Vardas, K, Rehn, M, Vaz-Ferreira, A, Weaver, A, Brohi, K, Lockey, D, Wright, S, Thomas, K, Mudersbach, E, Baker, C, Mansfield, L, Pozo, MO, Stafford, V, Wade, C, Watson, G, Silva, J, Bryant, A, Chadwick, T, Shen, J, Wilkinson, J, Kapuağası, A, Furneval, J, and Clinical Neurophysiology
- Subjects
Queen Square Neuroanaesthesia and Neurocritical Care Resreach Group ,TAVeM study Group ,Renal Transplantation HUVR ,Flow (psychology) ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Critical Care and Intensive Care Medicine ,Grupo ESBAGA ,GEMINI ,03 medical and health sciences ,chemistry.chemical_compound ,SPACeR group (Surrey Peri-operative, Anaesthesia and Critical Care Collaborative Research Group) ,0302 clinical medicine ,Critical Care Research Group ,Journal Article ,PRoVENT investigators and the PROVE Network ,Medicine ,Sedation an Delirium Group Hospital Universitari de Bellvitge ,030212 general & internal medicine ,Bioethics work group of SEMICYUC ,GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) ,SEMICYUC/GETGAG Working Group ,FINNAKI Study Group ,POPC-CB investigators ,business.industry ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,SIRAKI group ,030208 emergency & critical care medicine ,EDISVAL Group ,PLUG Working group ,DESIRE (DExmedetomidine for Sepsis in ICU Randomized Evaluation) Trial Investigators ,chemistry ,Anesthesia ,Carbon dioxide ,Breathing ,Department of Professional Development, ESICM ,business ,Nurses of the Central and General ICUs of Shiraz Namazi Hospital - Abstract
Contains fulltext : 172382.pdf (Publisher’s version ) (Open Access)
- Published
- 2016
11. Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department.
- Author
-
Pini F, Grigoriu B, Lieveke A, and Meert AP
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Aged, Belgium, Adult, Immune Checkpoint Inhibitors adverse effects, Emergency Service, Hospital statistics & numerical data, Neoplasms drug therapy
- Abstract
Introduction: With the rising use of immune checkpoint inhibitors ( ICIs ) in oncology, emergency physicians are increasingly confronted with their immune-related adverse events ( irAEs ). We described the types of irAEs presenting to the ED of a Belgian cancer centre and determined associations with the development of an irAE and other patient's characteristics. Secondary objectives describe the therapeutic management and determine 7 and 30-day mortality., Methods: A retrospective chart review of ED visits of patients on ICI from 15 December 2016 to 6 December 2020 was performed. Clinical presentation, cancer characteristics and type of ICI were extracted by a single abstractor. We recorded any suspicion of irAE in the ED and confirmation of an irAE was based on the patient's oncologist report. Outcome was based on mortality at date of last follow-up., Results: 227 patients on ICI presented to the ED, with a total of 451 visits. 54 (12%) of the visits resulted in a diagnosis of irAE. Four clinical features were associated with an irAE: gastrointestinal complaints (p=0.01), skin rashes (p=0.02), acute renal failure (p=0.002) and abnormal liver function (p=0.04). An irAE was also associated with three different factors: a cancer status in remission (OR=5.33, 95% CI 2.57 to 11.04), a combination of two ICIs (OR=4.43, 95% CI 2.09 to 9.42) and a medical history of irAE (OR=2.44, 95% CI 1.27 to 4.68). 30-day mortality was lower in the irAE group (0%) than in the non-irAE group (13%, 95% CI 9% to 19%)., Conclusions: Oncological patients under ICI presenting in the ED are more likely to have an irAE if they present with gastrointestinal and dermatological complaints, acute renal failure and abnormal liver function. This is also true for patients with any history of irAE, a concomitant use of two ICIs and with a cancer status in remission., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
12. Benefits of cardiopulmonary resuscitation in cancer patients.
- Author
-
Geelhand de Merxem M, Ameye L, and Meert AP
- Subjects
- Humans, Middle Aged, Male, Retrospective Studies, Female, Aged, Prognosis, Heart Arrest therapy, Aged, 80 and over, Adult, Age Factors, Intensive Care Units statistics & numerical data, Cardiopulmonary Resuscitation methods, Neoplasms complications, Neoplasms therapy, Hospital Mortality
- Abstract
Purpose: According to meta-analytic data, the prognosis of a cancer patient post-cardiopulmonary resuscitation (CPR) is relatively similar to the general population. However, preselection of patients, the details of CPR, patient-specific characteristics, and post-CPR care are poorly described. The aim of this study is to identify prognostic factors in order to recognize cancer patient profiles more likely to benefit from CPR., Methods: This is a retrospective study on a series of patients with solid or hematological malignancies who received CPR between January 2010 and December 2020 in a cancer institute., Results: Sixty-eight patients were included. The ratio of solid to hematological malignancy was 44/24, of which 32 were metastatic solid tumors. Median age was 61 years. Hypoxemia (29%) was the primary factor for cardiac arrest, followed by septic shock (21%). ICU mortality and hospital mortality were 87% and 88% respectively. Younger age, the presence of hematological malignancy, or a metastatic solid tumor were poor predictors for in-hospital mortality. Similarly, cardiac arrest in the ICU, as the final consequence of a pathological process, and a resuscitation time of more than 10 min have a negative influence on prognosis., Conclusions: This study shows that CPR is a useful intervention in cancer patients, even in the elderly patient, especially in non-metastatic solid tumors where cardiac arrest is the consequence of an acute event and not a terminal process., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
13. [Severe complications of systemic treatment in thoracic oncology].
- Author
-
Berghmans T, Brandão M, Ilzkovitz M, and Meert AP
- Subjects
- Humans, Emergencies, Mesothelioma drug therapy, Mesothelioma, Malignant, Thymoma pathology, Lung Neoplasms complications, Lung Neoplasms drug therapy, Pleural Neoplasms drug therapy
- Abstract
Primary thoracic cancers affect a large number of patients, mainly those with lung cancer and to a lesser extent those with pleural mesothelioma and thymic tumours. Given their frequency and associated comorbidities, in patients whose mean age is high, these diseases are associated with multiple complications. This article, the last of a series dedicated to emergencies in onco-haematological patients, aims to present a clinical picture of the severe complications (side effects, immune-related adverse events) associated with systemic treatments, excluding infections and respiratory emergencies, with which general practitioners and specialists can be confronted. New toxicities are to be expected with the implementation of innovative therapeutic approaches, such as CAR-T cells, along with immunomodulators and antibody-drug conjugates., (Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Leukemia cutis revealing relapse of a chronic myeloid leukemia: A case report.
- Author
-
Chérif A, Chérif MY, Trépant AL, Meert AP, and Ilzkovitz M
- Abstract
Key Clinical Message: Clinical presentation of leukemia cutis (LC) is polymorphic and can reveal a malignant hemopathy. More commonly described in cases of acute myeloid leukemia (AML), LC can also occur in case of chronic myeloid leukemia (CML)., Abstract: Leukemia cutis is a rare form of extramedullary feature of malignant hemopathy, seldom associated with CML. Its clinical presentation is pleiotropic and differential diagnosis is broad. It relies on clinical and typical histological and biomolecular concordance. Once confirmed, treatment is based on that of the primary condition. We present a case of a leukemia cutis revealing a relapse of a CML successfully treated by tyrosine kinase inhibitor., Competing Interests: The authors declare no conflicts of interest., (© 2024 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
15. Etiologies and Outcome of Patients with Solid Tumors Admitted to ICU with Acute Respiratory Failure: A Secondary Analysis of the EFRAIM Study.
- Author
-
Benguerfi S, Dumas G, Soares M, Meert AP, Martin-Loeches I, Pene F, Bauer P, Mehta S, Metaxa V, Burghi G, Kouatchet A, Montini L, Mokart D, Van de Louw A, Azoulay E, and Lemiale V
- Subjects
- Humans, Cohort Studies, Prospective Studies, Intensive Care Units, Hospital Mortality, Lung Neoplasms complications, Lung Neoplasms epidemiology, Respiratory Insufficiency epidemiology, Respiratory Insufficiency etiology
- Abstract
Background: Acute respiratory failure (ARF) remains the most frequent reason for ICU admission in patients who are immunocompromised. This study reports etiologies and outcomes of ARF in subjects with solid tumors., Methods: This study was a post hoc analysis of the EFRAIM study, a prospective multinational cohort study that included 1611 subjects who were immunocompromised and with ARF admitted to the ICU. Subjects with solid tumors admitted to the ICU with ARF were included in the analysis., Results: Among the subjects from the EFRAIM cohort, 529 subjects with solid tumors (32.8%) were included in the analysis. At ICU admission, the median (interquartile range) Sequential Organ Failure Assessment score was 5 (3-9). The types of solid tumor were mostly lung cancer ( n = 111, 21%), breast cancer ( n = 52, 9.8%), and digestive cancer ( n = 47, 8.9%). A majority, 379 subjects (71.6%) were full code at ICU admission. The ARF was caused by bacterial or viral infection ( n = 220, 41.6%), extrapulmonary sepsis ( n = 62, 11.7%), or related to cancer or treatment toxicity ( n = 83, 15.7%), or fungal infection ( n = 23, 4.3%). For 63 subjects (11.9%), the ARF etiology remained unknown after an extensive diagnostic workup. The hospital mortality rate was 45.7% ( n = 232/508). Hospital mortality was independently associated with chronic cardiac failure (odds ratio 1.78, 95% CI 1.09-2.92; P = .02), lung cancer (odds ratio 2.50, 95% CI 1.51-4.19; P < .001), day 1 Sequential Organ Failure Assessment score (odds ratio 1.97, 95% CI 1.32-2.96; P < .001). ARF etiologies other than infectious, related to cancer, or treatment toxicity were associated with better outcomes (odds ratio 0.32, 95% CI 0.16-0.61; P < .001)., Conclusions: Infectious diseases remained the most frequent cause of ARF in subjects with solid tumors admitted to the ICU. Hospital mortality was related to severity at ICU admission, previous comorbidities, and ARF etiologies related to non-malignant causes or pulmonary embolism. Lung tumor was also independently associated with higher mortality., Competing Interests: The authors have disclosed no conflicts of interest., (Copyright © 2023 by Daedalus Enterprises.)
- Published
- 2023
- Full Text
- View/download PDF
16. ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
- Author
-
Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, and Lemiale V
- Abstract
Background: Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs for ICU admissions in solid cancer patients treated with ICIs., Methods: This prospective multicenter study was conducted in France and Belgium. Adult patients with solid tumor and treated with systemic ICIs within the last 6 months, requiring non-programmed ICU admission were included. Patients admitted for microbiologically documented sepsis were excluded. Imputability of irAEs in ICU admissions was described according to the WHO-UMC classification system at ICU admission and at ICU discharge. The use of immunosuppressant treatment was reported., Results: 115 patients were eligible. Solid tumor was mainly lung cancer (n = 76, 66%) and melanoma (n = 18, 16%). They were mainly treated with an anti-PD-(L)1 alone (n = 110, 96%). Main ICU admission reasons were acute respiratory failure (n = 66, 57%), colitis (n = 14, 13%), and cardiovascular disease (n = 13, 11%). ICU admission was considered "likely" associated with irAE for 48% (n = 55) of patients. Factors independently associated with irAE were a good ECOG performance status (PS) (ECOG-PS of 0 or 1 vs. ECOG-PS of 2-3, odds ratio [OR] = 6.34, 95% confidence interval [95% CI] 2.13-18.90, and OR = 3.66, 95% CI 1.33-10.03, respectively), and a history of irAE (OR = 3.28, 95% CI 1.19-9.01). Steroids were prescribed for 41/55 (75%) patients with ICU admission "likely" related to irAE. Three patients were subsequently treated with immunosuppressants., Conclusion: IrAEs accounted for half of ICU admissions in cancer patients receiving ICIs. They could be treated with steroids. Identifying the imputability of irAEs in ICU admissions remains a challenge., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
17. Erratum to "When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study" [Bull. Cancer 109 (2022) 916-24].
- Author
-
Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van De Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, and Lemiale V
- Published
- 2023
- Full Text
- View/download PDF
18. [Respiratory cancer diseases: Which role for intensive care ?]
- Author
-
Berghmans T and Meert AP
- Subjects
- Humans, Critical Care, Intensive Care Units, Respiratory Tract Diseases, Respiration Disorders, Neoplasms, Respiratory Insufficiency
- Published
- 2023
- Full Text
- View/download PDF
19. European Respiratory Society guideline on various aspects of quality in lung cancer care.
- Author
-
Blum TG, Morgan RL, Durieux V, Chorostowska-Wynimko J, Baldwin DR, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hardavella G, Hauptmann M, Jakobsen E, Jovanovic D, Knaut P, Massard G, McPhelim J, Meert AP, Milroy R, Muhr R, Mutti L, Paesmans M, Powell P, Putora PM, Rawlinson J, Rich AL, Rigau D, de Ruysscher D, Sculier JP, Schepereel A, Subotic D, Van Schil P, Tonia T, Williams C, and Berghmans T
- Subjects
- Humans, Thorax, Societies, Medical, Lung pathology, Lung Neoplasms diagnosis, Lung Neoplasms therapy, Lung Neoplasms pathology
- Abstract
This European Respiratory Society guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO (Patients, Intervention, Comparison, Outcomes) questions. The evidence was appraised in compliance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence profiles and the GRADE Evidence to Decision frameworks were used to summarise results and to make the decision-making process transparent. A multidisciplinary Task Force panel of lung cancer experts formulated and consented the clinical recommendations following thorough discussions of the systematic review results. In particular, we have made recommendations relating to the following quality improvement measures deemed applicable to routine lung cancer care: 1) avoidance of delay in the diagnostic and therapeutic period, 2) integration of multidisciplinary teams and multidisciplinary consultations, 3) implementation of and adherence to lung cancer guidelines, 4) benefit of higher institutional/individual volume and advanced specialisation in lung cancer surgery and other procedures, 5) need for pathological confirmation of lesions in patients with pulmonary lesions and suspected lung cancer, and histological subtyping and molecular characterisation for actionable targets or response to treatment of confirmed lung cancers, 6) added value of early integration of palliative care teams or specialists, 7) advantage of integrating specific quality improvement measures, and 8) benefit of using patient decision tools. These recommendations should be reconsidered and updated, as appropriate, as new evidence becomes available., Competing Interests: Conflict of interest: T.G. Blum reports an unrestricted grant from Stiftung Oskar-Helene-Heim (Berlin, Germany), through which staff support for the work of the current Task Force was provided. R.L. Morgan declares no competing interests. V. Durieux declares no competing interests. J. Chorostowska-Wynimko declares grants to the National Institute of Tuberculosis and Lung Diseases from Pfizer and to the Polish Respiratory Society from AstraZeneca; consulting fees from AstraZeneca, Pfizer, Amgen, Takeda, Merck Sharp & Dohme, Roche and Roche Diagnostica; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Pfizer, CelonPharma, Amgen, Takeda, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Roche Diagnostica and Amoy; support for attending meetings and/or travel from Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Pfizer and Amgen; participation on a data safety monitoring board or advisory board for AstraZeneca, Pfizer, Takeda, Merck Sharp & Dohme, Roche and Roche Diagnostica, all in the 36 months prior to manuscript submission; and is Secretary General of the European Respiratory Society and a member of the Executive Committees of the Polish Respiratory Society and the Polish Coalition for Personalized Medicine. D.R. Baldwin declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol Myers Squibb, AstraZeneca, Roche and Merck Sharp & Dohme, all in the 36 months prior to manuscript submission. J. Boyd is an employee of the European Lung Foundation. C. Faivre-Finn reports research grants from AstraZeneca and Elekta; payment or honoraria for presentations from AstraZeneca; support for attending meetings and/or travel from Elekta and AstraZeneca; and participation on a data safety monitoring board or advisory board for AstraZeneca and Merck Sharp & Dohme, all in the 36 months prior to manuscript submission. F. Galateau-Salle declares no competing interests. F. Gamarra declares no competing interests. B. Grigoriu declares support for attending meetings and/or travel from Roche and AstraZeneca; and participation on a data safety monitoring board or advisory board for AstraZeneca, all in the 36 months prior to manuscript submission. G. Hardavella declares no competing interests. M. Hauptmann declares no competing interests. E. Jakobsen declares no competing interests. D. Jovanovic declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Merck Sharp & Dohme, Roche, Boehringer Ingelheim, WCBIP 2020 and AstraZeneca; payment for expert testimony relating to the health effects of air pollution from SO2 released by Serbia Zijin Copper mining and smelting complex and the two biggest Serbian power plants, all in the 36 months prior to manuscript submission; and is a member of the editorial boards of the Journal of Thoracic Disease and the AME Surgical Journal, and a committee member of the National Ecological Association (NEA), Serbia. P. Knaut declares no competing interests. G. Massard declares a speaker's fee from Pneumo Update Europe, in the 36 months prior to manuscript submission. J. McPhelim declares advisory board payments from AstraZeneca, Janssen-Cilag and Bristol Myers Squibb, all in the 36 months prior to manuscript submission. A-P. Meert declares no competing interests. R. Milroy declares no competing interests. R. Muhr declares no competing interests. L. Mutti declares no competing interests. M. Paesmans declares no competing interests. P. Powell is an employee of the European Lung Foundation. P.M. Putora declares research grants to their institution from AstraZeneca, Takeda and Bayer; and a speaker's fee from Janssen-Cilag, all in the 36 months prior to manuscript submission. J. Rawlinson declares travel/accommodation support from the BTOG to attend the annual meeting in Dublin as patient advocate/steering committee member; travel/accommodation support from the European Respiratory Society to attend a screening meeting in Barcelona (patient representative) and European Lung Foundation patient event at the European Respiratory Society Congress Madrid 2019; travel/accommodation support from the NCRI to attend a conference in Glasgow (consumer member); travel/accommodation support from the EORTC to attend the Patient Days event as a speaker and patient panel member; and has been a Non-Executive Director (lay member) at Sandwell and West Birmingham Clinical Commissioning Group, UK. A.L. Rich declares no competing interests. D. Rigau is a methodologist for the European Respiratory Society. D. de Ruysscher declares grants to their institution from AstraZeneca and BeiGene; payment to their institution for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca; and payment to their institution for participation on an advisory board from AstraZeneca, all in the 36 months prior to manuscript submission. J-P. Sculier declares no competing interests. A. Schepereel declares a research grant to their institution from Bristol Myers Squibb; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bristol Myers Squibb and Leo Pharma; support for attending meetings and/or travel from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme and Roche; and payment for participation on a data safety monitoring board or advisory board from AstraZeneca, Bristol Myers Squibb and Merck Sharp & Dohme, all in the 36 months prior to manuscript submission. D. Subotic declares no competing interests. P. Van Schil declares consulting fees paid to their institution by AstraZeneca and Merck Sharp & Dohme; payment to their institution for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca; and travel expenses related to participation in data safety monitoring or advisory boards for the LungART Trial and the Pearls Trial, all in the 36 months prior to manuscript submission; and is the President-elect of the International Association for the Study of Lung Cancer and the Treasurer of the Belgian Association for Cardio-Thoracic Surgery. T. Tonia is a methodologist for the European Respiratory Society. C. Williams is an employee of the European Lung Foundation. T. Berghmans declares consulting fees from InhaTarget; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen; and participation on a data safety monitoring board or advisory board for Janssen and Roche, all in the 36 months prior to manuscript submission., (Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2023
- Full Text
- View/download PDF
20. Sepsis-associated coagulopathy in onco-hematology patients presenting with thrombocytopenia: a multicentric observational study.
- Author
-
Lemiale V, Mabrouki A, Miry L, Mokart D, Pène F, Kouatchet A, Mayaux J, Bruneel F, Perez P, Meert AP, Moreau AS, Benoit D, Darmon M, Zafrani L, and Clere-Jehl R
- Subjects
- Humans, Intensive Care Units, Retrospective Studies, Fibrinogen, Shock, Septic, Sepsis, Blood Coagulation Disorders complications, Blood Coagulation Disorders diagnosis, Thrombocytopenia complications, Thrombocytopenia diagnosis, Hematology
- Abstract
Coagulation disorders increase mortality rate during septic shock, but the impact of concomitant hematological malignancies remains unknown. The study assessed coagulation disorders in onco-hematological patients with thrombocytopenia (<100 G/L) admitted to ICU for septic shock. Among 146 included patients, 50 patients had lymphoma and 49 patients had acute leukemia. ICU mortality rate was 43.8% ( n = 64). Median increase in prothrombin time (PT) at day(d) 1 was 4.7 s (IQR 3.2-7.9) in ICU survivors vs. 6.4 s (IQR 4.5-13.7; p < 0.01 ) in non-survivors. Fibrinogen kinetics (increase in fibrinogen levels between d1 and d2) was +0.55 (-0.22-1.55) vs. +0.10 g/L (-0.40-0.50; p = 0.03 ) in surviving and non-surviving patients, respectively. PT increase ≥6 s at d1 (OR 5.5; 95% CI 1.1-6.0; p = 0.03 ) and mechanical ventilation (OR 7.4; 95% CI 3.3-17.7; p < 0.001 ) were independently associated with ICU mortality. This study provides information and new ways to identify hematological patients with high-risk mortality.
- Published
- 2023
- Full Text
- View/download PDF
21. Optic neuritis in lung adenocarcinoma: A challenging diagnosis.
- Author
-
Goudsmit A, Brandao M, Oullai A, Engelman D, Ghorra N, Daif T, Buelens T, and Meert AP
- Subjects
- Humans, COVID-19 Vaccines, Microtubule-Associated Proteins, Nerve Tissue Proteins, Hydrolases, Immunoglobulin G, COVID-19, Optic Neuritis etiology, Optic Neuritis complications, Adenocarcinoma of Lung complications, Adenocarcinoma of Lung diagnosis, Lung Neoplasms complications, Lung Neoplasms diagnosis
- Abstract
Optic neuritis with CRMP-5 IgG is a paraneoplastic inflammation of the optic nerve associated with lung cancer, mostly small-cell lung cancer. We present the case of a patient with lung adenocarcinoma who developed progressive bilateral visual loss a few months after immune-chemotherapy with pembrolizumab and after Covid-19 vaccination. Positive CRMP-5 IgG were detected in blood sample and complete work-up - including brain MRI - did not show any progression. High dose systemic corticoids were administered with transient improving, followed by intravenous immunoglobulins, methotrexate and rituximab but despite negativization of CRMP-5 IgG, the patient had a progressive visual loss., Competing Interests: Conflicts of interest AG: no conflict of interest. MB: travel grant from Roche/GNE and Sanofi, speaker honorarium from Roche/GNE and Janssen (to my institution). AO: no conflict of interest. DE: no conflict of interest. TD: no conflict of interest. NG: no conflict of interest. TB: no conflict of interest. APM: grant from BMS outside the submitted work., (Copyright © 2022 SPLF and Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
22. When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study.
- Author
-
Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van De Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, and Lemiale V
- Subjects
- Adult, Aged, Hospital Mortality, Hospitalization, Humans, Middle Aged, Retrospective Studies, Survival Rate, Intensive Care Units, Neoplasms drug therapy
- Abstract
Purpose: To study prevalence of targeted therapy (TT)-related adverse events requiring ICU admission in solid tumor patients., Methods: Retrospective multicenter study from the Nine-i research group. Adult patients who received TT for solid tumor within 3 months prior to ICU admission were included. Patients admitted for TT-related adverse event were compared to those admitted for other reasons., Results: In total, 140 patients, median age of 63 (52-69) years were included. Primary cancer site was mostly digestive (n=27, 19%), kidney (n=27, 19%), breast (n=24, 17%), and lung (n=20, 14%). Targeted therapy was anti-VEGF/VEGFR for 27% (n=38) patients, anti-EGFR for 22% (n=31) patients, anti-HER2 for 14% (n=20) patients and anti-BRAF for 9% (n=5) patients. ICU admission was related to TT adverse events for 30 (21%) patients. The most frequent complications were interstitial pneumonia (n=7), cardiac failure (n=5), anaphylaxis (n=4) and bleeding (n=4). At ICU admission, no significant difference was found between patients admitted for a TT-related adverse event and the other patients. One-month survival rate was higher in patients admitted for TT adverse event (OR=5.733 [2.031-16.182] P<0.001)., Conclusions: Adverse events related to targeted therapy accounted for 20% of ICU admission in our population and carried a 16% one-month mortality. Outcome was associated with admission for TT related to adverse event, breast cancer and good performance status., (Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients.
- Author
-
Gueuning C, Ameye L, Loizidou A, Grigoriu B, and Meert AP
- Subjects
- COVID-19 Testing, Humans, Probability, Retrospective Studies, SARS-CoV-2, Sensitivity and Specificity, COVID-19 diagnosis, Neoplasms
- Abstract
Control of transmissible diseases as COVID-19 needs a testing and an isolation strategy. The PARIS score developed by Torjdman et al. was aimed at improving patient selection for testing and quarantining but was derived from a general population. We performed a retrospective analysis of the validity of the PARIS score in a cancer patient population. We included 164 patients counting for 181 visits at the emergency department of the Jules Bordet Institute between March 10th and May 18th which had a SARS-CoV-2 RT-PCR test at admission. Twenty-six cases (14.3%) were tested positive with a higher proportion of positive tests among hematological patients compared to those with solid tumors (26% vs 11% p = 0.02). No clinical symptoms were associated with a positive SARS-CoV-2 PCR. No association between anticancer treatment and SARS-CoV-2 infection was found. The PARIS score failed to differentiate SARS-CoV-2-positive and SARS-CoV-2-negative groups (AUC 0.61 95% CI 0.48-0.73). The negative predictive value of a low probability PARIS score was 0.89 but this concerned only 11% of the patients. A high probability PARIS score concerned 49% patients but the positive predictive value was 0.18. CT scan had a sensitivity of 0.77, specificity 0.51, a positive predictive value of 0.24, and a negative predictive value of 0.92. The performance of the PARIS score is thus very poor in this cancer population. A low-risk score can be of some utility but this concerns a minority of patients., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
24. Characteristics and Outcomes of Patients in the ICU With Respiratory Syncytial Virus Compared With Those With Influenza Infection: A Multicenter Matched Cohort Study.
- Author
-
Coussement J, Zuber B, Garrigues E, Gros A, Vandueren C, Epaillard N, Voiriot G, Tandjaoui-Lambiotte Y, Lascarrou JB, Boissier F, Lemiale V, Contou D, Hraiech S, Meert AP, Sauneuf B, Munting A, Ricome S, Messika J, Muller G, Njimi H, and Grimaldi D
- Subjects
- Adult, Cohort Studies, Hospital Mortality, Hospitalization, Humans, Intensive Care Units, Retrospective Studies, Influenza, Human complications, Influenza, Human diagnosis, Influenza, Human epidemiology, Respiratory Syncytial Virus Infections complications, Respiratory Syncytial Virus Infections diagnosis, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus, Human
- Abstract
Background: The characteristics and outcomes of adult patients with respiratory syncytial virus (RSV) infection who require ICU admission are poorly defined. Although several studies in adults with RSV infection have been published in recent years, they did not focus specifically on patients with critical illness., Research Question: What are the characteristics and outcomes of adult patients in the ICU with RSV infection and how do they compare with those of patients in the ICU with influenza infection?, Study Design and Methods: This retrospective, multicenter study in France and Belgium (17 sites) compared the characteristics and outcomes of adult patients in the ICU with RSV infection vs those with influenza infection between November 2011 and April 2018. Each patient with RSV infection was matched by institution and date of diagnosis with a patient with influenza infection. In-hospital mortality was compared between the two groups, with adjustment for prognostic factors in a multivariate model (sex, age, main underlying conditions, and concurrent bloodstream infection)., Results: Data from 618 patients (309 with RSV infection and 309 with influenza infection) were analyzed. Patients with RSV infection were significantly more likely to have an underlying chronic respiratory condition (60.2% vs 40.1%; P < .001) and to be immunocompromised (35% vs 26.2%; P = .02) than patients with influenza infection. Several differences in clinical signs and biological data at diagnosis were found between the groups. In-hospital mortality was not significantly different between the two groups (23.9% in the RSV group vs 25.6% in the influenza group; P = .63), even after adjustment for prognostic factors in a multivariate model., Interpretation: Adult patients in the ICU with RSV infection differ from adult patients in the ICU with influenza in terms of comorbidities and characteristics at diagnosis. RSV infection was associated with high in-hospital mortality, approaching 25%. In multivariate analysis, RSV infection was associated with a similar odds of in-hospital death compared with influenza infection., (Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Initiation of a new anti-cancer medical treatment in ICU: a retrospective study.
- Author
-
Chicoisneau M, Paesmans M, Ameye L, Sculier JP, and Meert AP
- Subjects
- Critical Illness, Female, Hospital Mortality, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Intensive Care Units, Neoplasms drug therapy
- Abstract
Purpose: The purpose of our study is to evaluate the characteristics of patients whose medical anti-cancer treatment has been initiated at the ICU and to release prognostic factors for hospital mortality in these patients., Material and Methods: We analyzed retrospectively all the records of cancer patients admitted between 01/01/2007 and 31/12/2017 in our ICU and for whom a new anti-cancer medical treatment was initiated during their ICU stay., Results: Our study includes 147 patients, 78 men (53%) and 69 women (47%), with a median age of 58 years. Eighty patients (54%) had a solid tumor and 67 (46%) a hematological malignancy. ICU mortality was 23% and hospital mortality 32%. The poor prognostic factors for hospital mortality were: higher SOFA, higher Charslon comorbidity index and the presence of a therapeutic limitation (introduced at the time of admission or within 24 hours of admission to the ICU). One-year survival for patients who survived hospital stay was 37% (17% for those with a solid tumor and 61% for the ones with a hematological malignancy)., Conclusion: Initiation of an anti-cancer medical treatment is feasible and can lead to good 1 year survival rate, especially for those with a hematological tumor.
- Published
- 2022
- Full Text
- View/download PDF
26. [The role of the intensive care unit after thoracic surgery].
- Author
-
Fontana V, Coureau M, Grigoriu B, Tamburini N, Lemaitre J, and Meert AP
- Subjects
- Humans, Intensive Care Units, Pneumonectomy, Postoperative Complications epidemiology, Postoperative Complications etiology, Lung Neoplasms epidemiology, Lung Neoplasms surgery, Thoracic Surgery, Thoracic Surgical Procedures
- Abstract
Lung (bronchial) cancer is the leading cause of cancer-related death in Western countries today. Thoracic surgery represents a major therapeutic strategy and the various advances made in recent years have made it possible to develop less and less invasive techniques. That said, the postoperative period may be lengthy, post-surgical approaches need to be more precisely codified, and it matters that the different interventions involved be supported by sound scientific evidence. To date, however, there exists no evidence that preventive postoperative admission to intensive care is beneficial for patients having undergone lung resection surgery without immediate complications. A stratification of the risk of complications taking into consideration the patient's general state of health (e.g., nutritional status, degree of autonomy, etc.), comorbidities and type of surgery could be a useful predictive tool regarding the need for postoperative intensive care. However, serious post-operative complications remain relatively frequent and post-operative management of these intensive care patients is liable to become complex and long-lasting. In the aftermath of the validation of "enhanced recovery after surgery" (ERAS) in thoracic surgery, new protocols are needed to optimize management of patients having undergone pulmonary resection. This article focuses on the main postoperative complications and more broadly on intensive care patient management following thoracic surgery., (Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.
- Author
-
Goudsmit A, Cubilier E, Meert AP, Aftimos P, Stathopoulos K, Spilleboudt C, and Loizidou A
- Subjects
- Adult, COVID-19 Testing, Humans, Middle Aged, Retrospective Studies, SARS-CoV-2, COVID-19, Hematologic Neoplasms epidemiology, Neoplasms epidemiology
- Abstract
Background: Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies., Method: This retrospective single oncologic center study included adults with solid tumors or hematological malignancies referred to testing by naso-pharyngeal swab for a SARS-CoV-2 RT-PCR from March 10 to May 18, 2020., Results: A total of 212 patients were included in the study. Forty-five (21%) were tested positive with SARS-CoV-2. The univariate analysis with positive SARS-CoV-2 PCR as a dependent variable reveals significant odds ratios (ORs) for age-with a mean of 62.5 years-(OR: 1.05, 95% CI: 1.02-1.08), performance status ≥2 (OR: 2.38, 95% CI: 1.22-4.70), inpatient status (OR: 2.36, 95%CI: 1.11-4.91), and hematological malignancies (OR: 2.48, 95% CI: 1.23-4.96). In contrast, OR for solid tumors reveals a negative association (OR: 0.40, 95% CI: 0.20-0.81). When integrating severe outcome (ICU admission or COVID-19-related death) as a dependent variable, the univariate logistic regression model shows significant ORs for pre-existing lymphopenia (OR: 4.0, 95% CI: 1.17-15.04), hematological malignancies (OR: 3.73, 95% CI: 1.09-13.80), and a negative association for solid tumors (OR: 0.27; 95% CI: 0.07-0.92)., Conclusion: In patients referred for SARS-CoV-2 testing, hematological malignancies were associated with a higher risk of COVID-19 infection and severe outcomes. Other factors were age and inpatient status., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
28. Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference.
- Author
-
Meert AP, Wittnebel S, Holbrechts S, Toffart AC, Lafitte JJ, Piagnerelli M, Lemaitre F, Peyrony O, Calvel L, Lemaitre J, Canet E, Demoule A, Darmon M, Sculier JP, Voigt L, Lemiale V, Pène F, Schnell D, Lengline E, Berghmans T, Fiévet L, Jungels C, Wang X, Bold I, Pistone A, Salaroli A, Grigoriu B, and Benoit D
- Subjects
- Belgium, Critical Care, Humans, Intensive Care Units, Respiration, Artificial, Systematic Reviews as Topic, Critical Illness, Neoplasms therapy
- Abstract
To respond to the legitimate questions raised by the application of invasive methods of monitoring and life-support techniques in cancer patients admitted in the ICU, the European Lung Cancer Working Party and the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, set up a consensus conference. The methodology involved a systematic literature review, experts' opinion and a final consensus conference about nine predefined questions1. Which triage criteria, in terms of complications and considering the underlying neoplastic disease and possible therapeutic limitations, should be used to guide admission of cancer patient to intensive care units?2. Which ventilatory support [High Flow Oxygenation, Non-invasive Ventilation (NIV), Invasive Mechanical Ventilation (IMV), Extra-Corporeal Membrane Oxygenation (ECMO)] should be used, for which complications and in which environment?3. Which support should be used for extra-renal purification, in which conditions and environment?4. Which haemodynamic support should be used, for which complications, and in which environment?5. Which benefit of cardiopulmonary resuscitation in cancer patients and for which complications?6. Which intensive monitoring in the context of oncologic treatment (surgery, anti-cancer treatment …)?7. What specific considerations should be taken into account in the intensive care unit?8. Based on which criteria, in terms of benefit and complications and taking into account the neoplastic disease, patients hospitalized in an intensive care unit (or equivalent) should receive cellular elements derived from the blood (red blood cells, white blood cells and platelets)?9. Which training is required for critical care doctors in charge of cancer patients?, (© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
29. Outcomes of ICU patients with and without perceptions of excessive care: a comparison between cancer and non-cancer patients.
- Author
-
Benoit DD, van der Zee EN, Darmon M, Reyners AKL, Metaxa V, Mokart D, Wilmer A, Depuydt P, Hvarfner A, Rusinova K, Zijlstra JG, Vincent F, Lathyris D, Meert AP, Devriendt J, Uyttersprot E, Kompanje EJO, Piers R, and Azoulay E
- Abstract
Background: Whether Intensive Care Unit (ICU) clinicians display unconscious bias towards cancer patients is unknown. The aim of this study was to compare the outcomes of critically ill patients with and without perceptions of excessive care (PECs) by ICU clinicians in patients with and without cancer., Methods: This study is a sub-analysis of the large multicentre DISPROPRICUS study. Clinicians of 56 ICUs in Europe and the United States completed a daily questionnaire about the appropriateness of care during a 28-day period. We compared the cumulative incidence of patients with concordant PECs, treatment limitation decisions (TLDs) and death between patients with uncontrolled and controlled cancer, and patients without cancer., Results: Of the 1641 patients, 117 (7.1%) had uncontrolled cancer and 270 (16.4%) had controlled cancer. The cumulative incidence of concordant PECs in patients with uncontrolled and controlled cancer versus patients without cancer was 20.5%, 8.1%, and 9.1% (p < 0.001 and p = 0.62, respectively). In patients with concordant PECs, we found no evidence for a difference in time from admission until death (HR 1.02, 95% CI 0.60-1.72 and HR 0.87, 95% CI 0.49-1.54) and TLDs (HR 0.81, 95% CI 0.33-1.99 and HR 0.70, 95% CI 0.27-1.81) across subgroups. In patients without concordant PECs, we found differences between the time from admission until death (HR 2.23, 95% CI 1.58-3.15 and 1.66, 95% CI 1.28-2.15), without a corresponding increase in time until TLDs (NA, p = 0.3 and 0.7) across subgroups., Conclusions: The absence of a difference in time from admission until TLDs and death in patients with concordant PECs makes bias by ICU clinicians towards cancer patients unlikely. However, the differences between the time from admission until death, without a corresponding increase in time until TLDs, suggest prognostic unawareness, uncertainty or optimism in ICU clinicians who did not provide PECs, more specifically in patients with uncontrolled cancer. This study highlights the need to improve intra- and interdisciplinary ethical reflection and subsequent decision-making at the ICU., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
30. Correction to: Performance of the ROX index to predict intubation in immunocompromised patients receiving high-flow nasal cannula for acute respiratory failure.
- Author
-
Lemiale V, Dumas G, Demoule A, Pène F, Kouatchet A, Bisbal M, Nseir S, Argaud L, Kontar L, Klouche K, Barbier F, Seguin A, Louis G, Constantin JM, Mayaux J, Wallet F, Peigne V, Girault C, Oziel J, Nyunga M, Terzi N, Bouadma L, Lautrette A, Bige N, Raphalen JH, Papazian L, Bruneel F, Lebert C, Benoit D, Meert AP, Jaber S, Mokart D, Darmon M, and Azoulay E
- Published
- 2021
- Full Text
- View/download PDF
31. Drug-related problems and risk factors related to unplanned hospital readmission among cancer patients in Belgium.
- Author
-
Koubaity M, Lechon AS, Amighi K, Van Nuffelen M, Moreau M, Meert AP, and De Vriese C
- Subjects
- Aged, Aged, 80 and over, Belgium, Female, Humans, Male, Retrospective Studies, Risk Factors, Drug-Related Side Effects and Adverse Reactions epidemiology, Neoplasms complications, Patient Readmission statistics & numerical data
- Abstract
Introduction: There are about 60,000 diagnoses of cancer per year in Belgium. After hospital care, about 12-13% of cancer patients are readmitted within 30 days after discharge. These readmissions are partly related to drug-related problems (DRP), such as interactions or adverse drug effects (ADE)., Objectives: The aim of this study is to quantify and to classify DRP readmissions within 30 days for cancer patients and to highlight risk factors potentially correlated to readmissions., Methods: This study is a 6-month observational retrospective study in two care facilities in Brussels: an academic general hospital and an academic oncology center. Patients readmitted within 30 days after their last hospital care for a potential DRP were included. Patient files were evaluated with an intermediate medication review that included interactions analysis (Lexicomp®). The probability of DRP readmission was assessed using the World Health Organization's Uppsala Monitoring Centre (WHO-UMC) system., Results: The final population included 299 patients; among them, 123 (41.1%) were readmitted due to DRP (certain DRP (4.9%), probable DRP (49.6%), and possible DRP (45.5%)). Risks factors linked to these DRP were a low Charlson Comorbidity Index, polypharmacy, the kind of hospital, and some chemotherapies (platinum preparations). Among all readmitted patients, the D-type interactions were the most common (44.8%), which suggest a possible therapy modification. However, around 10% of interactions were X-type (drug combination to avoid)., Conclusion: Almost 10% of patient readmitted within 30 days were potentially related to a DRP, most of them from adverse drug effects. Four risk factors (low Charlson Comorbidity Index, polypharmacy, the hospital, and some chemotherapies) were highlighted to prevent these readmissions.
- Published
- 2021
- Full Text
- View/download PDF
32. Impact of early ICU admission for critically ill cancer patients: Post-hoc analysis of a prospective multicenter multinational dataset.
- Author
-
Hourmant Y, Kouatchet A, López R, Mokart D, Pène F, Mayaux J, Bruneel F, Lebert C, Renault A, Meert AP, Benoit D, Lemiale V, Azoulay E, and Darmon M
- Subjects
- Hospital Mortality, Humans, Intensive Care Units, Prospective Studies, Retrospective Studies, Critical Illness, Neoplasms therapy
- Abstract
Objectives: Early intensive care unit (ICU) admission, in Critically Ill Cancer Patients (CICP), is believed to have contributed to the prognostic improvement of critically ill cancer patients. The primary objective of this study was to assess the association between early ICU admission and hospital mortality in CICP., Design: Retrospective analysis of a prospective multicenter dataset. Early admission was defined as admission in the ICU < 24 h of hospital admission. We assessed the association between early ICU admission and hospital mortality in CICP via survival analysis and propensity score matching., Results: Of the 1011patients in our cohort, 1005 had data available regarding ICU admission timing and were included. Overall, early ICU admission occurred in 455 patients (45.3%). Crude hospital mortality in patients with early and delayed ICU admission was 33.6% (n = 153) vs. 43.1% (n = 237), respectively (P = 0.02). After adjustment for confounders, early compared to late ICU admission was not associated with hospital mortality (HR 0.92; 95%CI 0.76-1.11). After propensity score matching, hospital mortality did not differ between patients with early (35.2%) and late (40.6%) ICU admission (P = 0.13). In the matched cohort, early ICU admission was not associated with mortality after adjustment on SOFA score (HR 0.89; 95%CI 0.71-1.12). Similar results were obtained after adjustment for center effect., Conclusion: In this cohort, early ICU admission was not associated with a better outcome after adjustment for confounder and center effect. The uncertainty with regard to the beneficial effect of early ICU on hospital mortality suggests the need for an interventional study., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Hepatic dysfunction impairs prognosis in critically ill patients with hematological malignancies: A post-hoc analysis of a prospective multicenter multinational dataset.
- Author
-
Bisbal M, Darmon M, Saillard C, Mallet V, Mouliade C, Lemiale V, Benoit D, Pene F, Kouatchet A, Demoule A, Vincent F, Nyunga M, Bruneel F, Lebert C, Renault A, Meert AP, Hamidfar R, Jourdain M, Azoulay E, and Mokart D
- Subjects
- Critical Illness, Hospital Mortality, Humans, Intensive Care Units, Prognosis, Prospective Studies, Hematologic Neoplasms complications, Hematologic Neoplasms epidemiology, Liver Diseases
- Abstract
Purpose: Hyperbilirubinemia is frequent in patients with hematological malignancies admitted to the intensive care unit (ICU). Literature about hepatic dysfunction (HD) in this context is scarce., Methods: We investigated the prognostic impact of HD analyzing a prospective multicenter cohort of 893 critically ill hematology patients. Two groups were defined: patients with HD (total bilirubin ≥33 μmol/L at ICU admission) and patients without HD., Results: Twenty one percent of patients were found to have HD at ICU admission. Cyclosporine, antimicrobials before ICU admission, abdominal symptoms, ascites, history of liver disease, neutropenia, increased serum creatinine and myeloma were independently associated with HD. Etiology remained undetermined in 73% of patients. Hospital mortality was 56.3% and 36.3% respectively in patients with and without HD (p < 0.0001). Prognostic factors independently associated with hospital mortality in HD group were, performance status >1 (OR = 2.07, 95% CI = 1.49-2.87, p < 0.0001), invasive mechanical ventilation (OR = 3.92, 95% CI = 2.69-5.71, p < 0.0001), renal replacement therapy (OR = 1.74, 95% CI = 1.22-2.47, p = 0.002), vasoactive drug (OR = 1.81, 95% CI = 1.21-2.71, p = 0.004) and SOFA score without bilirubin level at ICU admission (OR = 1.09, 95% CI = 1.04-1.14, p < 0.0001)., Conclusions: HD is common, underestimated, infrequently investigated, and is associated with impaired outcome in critically ill hematology patients. HD should be considered upon ICU admission and managed as other organ dysfunctions., Competing Interests: Declaration of Competing Interest None., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
34. Sepsis and Septic Shock Definitions in Patients With Cancer Admitted in ICU.
- Author
-
Nathan N, Sculier JP, Ameye L, Paesmans M, Bogdan-Dragos G, and Meert AP
- Subjects
- Hospital Mortality, Humans, Intensive Care Units, Prognosis, ROC Curve, Reproducibility of Results, Retrospective Studies, Systemic Inflammatory Response Syndrome, Neoplasms complications, Sepsis classification, Sepsis diagnosis, Shock, Septic classification, Shock, Septic diagnosis
- Abstract
Introduction: In 2016, a new definition of sepsis and septic shock was adopted. Some studies based on the general population demonstrated that the Sequential Organ Failure Assessment (SOFA) score is more accurate than the systemic inflammatory response syndrome (SIRS) criteria to predict hospital mortality of infected patients requiring intensive care., Patients and Method: We have analyzed all the records of patients with cancer admitted for a suspected infection between January 1, 2013, and December 31, 2016, in our oncological intensive care unit (ICU). Sequential Organ Failure Assessment score and quick SOFA (qSOFA) score as well as SIRS criteria were calculated. We analyzed the accuracy of each score to predict hospital mortality in the setting of the new and old definitions of septic shock., Results: Our study includes 241 patients with a solid tumor and 112 with a hematological malignancy. The hospital mortality rate is 37% (68% in patients with septic shock according to the new definition and 60% according to old definition) between 2013 and 2016. To predict hospital mortality, the SOFA score has an area under the receiver operating characteristic curve of 0.74 (95% confidence interval [CI], 0.68-0.79), the qSOFA of 0.65 (95% CI, 0.59-0.70), and the SIRS criteria of 0.58 (95% CI, 0.52-0.63). In multivariate analysis, a higher SOFA score or a higher qSOFA score indicates poor prognosis: odds ratio (OR) per 1-point increase by 1.28 (95% CI, 1.18-1.39) and 1.48 (95% CI, 1.04-2.11), respectively. Complete remission is a good prognostic factor for hospital mortality: OR 0.39 (95% CI, 0.22-0.67)., Conclusion: The new definition of sepsis and septic shock is applicable in an ICU oncological population with the same reliability as in the general population. The SOFA score is more accurate than qSOFA and SIRS criteria to predict hospital mortality.
- Published
- 2021
- Full Text
- View/download PDF
35. [The role of prophylactic cranial irradiation in small cell lung cancer].
- Author
-
Fievet L, Sculier JP, Meert AP, and Berghmans T
- Subjects
- Cranial Irradiation, Humans, Neoplasm Recurrence, Local, Retrospective Studies, Brain Neoplasms prevention & control, Brain Neoplasms secondary, Lung Neoplasms radiotherapy, Small Cell Lung Carcinoma radiotherapy
- Abstract
Introduction: Prophylactic cranial irradiation (PCI) is considered standard therapeutic management in small cell lung cancer (SCLC). This is based on old randomised trials with methodological limitations, namely the absence of magnetic resonance imaging (MRI) of the brain. The aim of this study is to assess the risk not administering PCI when systematic brain imaging is applied., Methods: Retrospective study including untreated SCLC, without PCI and receiving brain imaging at the time of diagnosis. Kaplan-Meier and log-rank statistics were used for survival analyses., Results: Among 150 patients, 75 were possibly eligible for PCI. Thirteen patients presented with an isolated brain recurrence as the first site of progression with no other metastatic sites apparent, and in 6 patients, the brain was the only recurrent site during the whole follow-up. In the group of patients eligible for PCI, there was no statistically significant survival difference according to the brain progression status (P=0.11)., Conclusions: The expected impact of PCI seems limited in terms of overall survival and prevention of isolated brain metastases in patients having systematic brain imaging during SCLC work-up., (Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
36. Performance of the ROX index to predict intubation in immunocompromised patients receiving high-flow nasal cannula for acute respiratory failure.
- Author
-
Lemiale V, Dumas G, Demoule A, Pène F, Kouatchet A, Bisbal M, Nseir S, Argaud L, Kontar L, Klouche K, Barbier F, Seguin A, Louis G, Constantin JM, Mayaux J, Wallet F, Peigne V, Girault C, Oziel J, Nyunga M, Terzi N, Bouadma L, Lautrette A, Bige N, Raphalen JH, Papazian L, Bruneel F, Lebert C, Benoit D, Meert AP, Jaber S, Mokart D, Darmon M, and Azoulay E
- Abstract
Background: Delayed intubation is associated with high mortality. There is a lack of objective criteria to decide the time of intubation. We assessed a recently described combined oxygenation index (ROX index) to predict intubation in immunocompromised patients. The study is a secondary analysis of randomized trials in immunocompromised patients, including all patients who received high-flow nasal cannula (HFNC). The first objective was to evaluate the accuracy of the ROX index to predict intubation for patients with acute respiratory failure., Results: In the study, 302 patients received HFNC. Acute respiratory failure was mostly related to pneumonia (n = 150, 49.7%). Within 2 (1-3) days, 115 (38.1%) patients were intubated. The ICU mortality rate was 27.4% (n = 83). At 6 h, the ROX index was lower for patients who needed intubation compared with those who did not [4.79 (3.69-7.01) vs. 6.10 (4.48-8.68), p < 0.001]. The accuracy of the ROX index to predict intubation was poor [AUC = 0.623 (0.557-0.689)], with low performance using the threshold previously found (4.88). In multivariate analysis, a higher ROX index was still independently associated with a lower intubation rate (OR = 0.89 [0.82-0.96], p = 0.04)., Conclusion: A ROX index greater than 4.88 appears to have a poor ability to predict intubation in immunocompromised patients with acute respiratory failure, although it remains highly associated with the risk of intubation and may be useful to stratify such risk in future studies.
- Published
- 2021
- Full Text
- View/download PDF
37. Acute Respiratory Failure Outcomes in Patients with Hematologic Malignancies and Hematopoietic Cell Transplant: A Secondary Analysis of the EFRAIM Study.
- Author
-
Munshi L, Darmon M, Soares M, Pickkers P, Bauer P, Meert AP, Martin-Loeches I, Staudinger T, Pene F, Antonelli M, Barratt-Due A, Demoule A, Metaxa V, Lemiale V, Taccone F, Mokart D, Azoulay E, and Mehta S
- Subjects
- Adult, Humans, Prospective Studies, Transplantation, Homologous, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Respiratory Insufficiency etiology
- Abstract
Patients with allogeneic hematopoietic cell transplantation (HCT) who develop acute respiratory failure (ARF) are perceived to have worse outcomes than autologous HCT recipients and non-transplant patients with hematologic malignancy (HM). Within a large international prospective cohort, we evaluated clinical outcomes in these 3 populations. We conducted a secondary analysis of the EFRAIM study, a multicenter observational study of immunocompromised adults with ARF admitted to 62 intensive care units (ICUs) in 16 countries. We described characteristics and compared outcomes of patients with HM who did not undergo transplantation and patients who underwent autologous or allogeneic HCT using multivariable logistic regression and propensity score-matched analyses. A total of 801 patients were included: 570 who did not undergo transplantation, 86 autologous HCT recipients and 145 allogeneic HCT recipients. Acute myelogenous leukemia (171 of 570; 30%) was the most common HM and most common indication for allogeneic HCT (76 of 145; 52%). Compared with the patients who did not undergo HCT and autologous HCT recipients, allogeneic HCT recipients were younger, had fewer comorbid conditions, and were more likely to undergo diagnostic bronchoscopy in the ICU. Unadjusted ICU and hospital mortality were 35% and 45%, respectively, across the entire cohort. In multivariable regression analysis, autologous HCT (odds ratio [OR], 1.07; 95% confidence interval [CI], .57 to 2.03; P = .82) and allogeneic HCT (OR, .99; 95% CI, .60 to 1.66; P = .98) were not associated with higher hospital mortality compared with the no-HCT cohort, adjusting for demographic, functional, clinical, malignancy, and ARF characteristics. The results were similar when analyzed using propensity score-matching techniques. Our findings indicate that autologous and allogeneic HCT recipients who develop ARF and require ICU admission have similar hospital mortality as patients with HM not treated with HCT., (Copyright © 2020 The American Society for Transplantation and Cellular Therapy. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Oxygenation Strategy During Acute Respiratory Failure in Critically-Ill Immunocompromised Patients.
- Author
-
Lemiale V, De Jong A, Dumas G, Demoule A, Mokart D, Pène F, Kouatchet A, Bisbal M, Bruneel F, Lebert C, Vinatier I, Benoit D, Meert AP, Jaber S, Darmon M, and Azoulay E
- Subjects
- Cross Infection epidemiology, Humans, Intensive Care Units statistics & numerical data, Length of Stay, Lung pathology, Organ Dysfunction Scores, Respiratory Insufficiency epidemiology, Respiratory Insufficiency mortality, Severity of Illness Index, Critical Illness therapy, Immunocompromised Host physiology, Intubation, Intratracheal statistics & numerical data, Oxygen Inhalation Therapy methods, Respiratory Insufficiency therapy
- Abstract
Objectives: To assess the response to initial oxygenation strategy according to clinical variables available at admission., Design: Multicenter cohort study., Setting: Thirty French and Belgium medical ICU., Subjects: Immunocompromised patients with hypoxemic acute respiratory failure., Interventions: None., Measurements and Main Results: Data were extracted from the Groupe de Recherche en Reanimation Respiratoire du patient d'Onco-Hématologie database. Need for invasive mechanical ventilation was the primary endpoint. Secondary endpoint was day-28 mortality. Six-hundred forty-nine patients were included. First oxygenation strategies included standard oxygen (n = 245, 38%), noninvasive ventilation (n = 285; 44%), high-flow nasal cannula oxygen (n = 55; 8%), and noninvasive ventilation + high-flow nasal cannula oxygen (n = 64; 10%). Bilateral alveolar pattern (odds ratio = 1.67 [1.03-2.69]; p = 0.04), bacterial (odds ratio = 1.98 [1.07-3.65]; p = 0.03) or opportunistic infection (odds ratio = 4.75 [2.23-10.1]; p < 0.001), noninvasive ventilation use (odds ratio = 2.85 [1.73-4.70]; p < 0.001), Sequential Organ Failure Assessment score (odds ratio = 1.19 [1.10-1.28]; p < 0.001), and ratio of PaO2 and FIO2 less than 100 at ICU admission (odds ratio = 1.96 [1.27-3.02]; p = 0.0002) were independently associated with intubation rate. Day-28 mortality was independently associated with bacterial (odds ratio = 2.34 [1.10-4.97]; p = 0.03) or opportunistic infection (odds ratio = 4.96 [2.11-11.6]; p < 0.001), noninvasive ventilation use (odds ratio = 2.35 [1.35-4.09]; p = 0.003), Sequential Organ Failure Assessment score (odds ratio = 1.19 [1.10-1.28]; p < 0.001), and ratio of PaO2 and FIO2 less than 100 at ICU admission (odds ratio = 1.97 [1.26-3.09]; p = 0.003). High-flow nasal cannula oxygen use was neither associated with intubation nor mortality rates., Conclusions: Some clinical characteristics at ICU admission including etiology and severity of acute respiratory failure enable to identify patients at high risk for intubation.
- Published
- 2020
- Full Text
- View/download PDF
39. Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study.
- Author
-
Lemiale V, Pons S, Mirouse A, Tudesq JJ, Hourmant Y, Mokart D, Pène F, Kouatchet A, Mayaux J, Nyunga M, Bruneel F, Meert AP, Borcoman E, Bisbal M, Legrand M, Benoit D, Azoulay E, Darmon M, and Zafrani L
- Subjects
- Aged, Critical Illness, Europe epidemiology, Female, Hematologic Neoplasms epidemiology, Hospital Mortality, Humans, Male, Middle Aged, Neoplasms mortality, Respiration, Artificial, Risk Factors, Sepsis mortality, Shock, Septic epidemiology, Survival Rate, Time Factors, Intensive Care Units statistics & numerical data, Neoplasms epidemiology, Sepsis epidemiology
- Abstract
Objectives: Cancer affects up to 20% of critically ill patients, and sepsis is one of the leading reasons for ICU admission in this setting. Early signals suggested that survival might be increasing in this population. However, confirmation studies have been lacking. The goal of this study was to assess trends in survival rates over time in cancer patients admitted to the ICU for sepsis or septic shock over the last 2 decades., Data Source: Seven European ICUs., Study Selection: A hierarchical model taking into account the year of admission and the source dataset as random variables was used to identify risk factors for day 30 mortality., Data Extraction: Data from cancer patients admitted to ICUs for sepsis or septic shock were extracted from the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique database (1994-2015)., Data Synthesis: Overall, 2,062 patients (62% men, median [interquartile range] age 59 yr [48-67 yr]) were included in the study. Underlying malignancies were solid tumors (n = 362; 17.6%) or hematologic malignancies (n = 1,700; 82.4%), including acute leukemia (n = 591; 28.7%), non-Hodgkin lymphoma (n = 461; 22.3%), and myeloma (n = 244; 11.8%). Two-hundred fifty patients (12%) underwent allogeneic hematopoietic stem cell transplantation and 640 (31.0%) were neutropenic at ICU admission. Day 30 mortality was 39.9% (823 deaths). The year of ICU admission was associated with significant decrease in day 30 mortality over time (odds ratio, 0.96; 95% CI, 0.93-0.98; p = 0.001). Mechanical ventilation (odds ratio, 3.25; 95% CI, 2.52-4.19; p < 0.01) and vasopressors use (odds ratio, 1.42; 95% CI, 1.10-1.83; p < 0.01) were independently associated with day 30 mortality, whereas underlying malignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia were not., Conclusions: Survival in critically ill oncology and hematology patients with sepsis improved significantly over time. As outcomes improve, clinicians should consider updating admission policies and goals of care in this population.
- Published
- 2020
- Full Text
- View/download PDF
40. Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.
- Author
-
Coureau M, Meert AP, Berghmans T, and Grigoriu B
- Abstract
Immunotherapy is an important armamentarium for cancer treatment nowadays. Apart from their significant effectiveness in controlling disease they also generate potential severe immune related adverse effects. Preexistence of immune related conditions may eventually predispose to the development of more severe complication and extreme caution have been taken in treating these patients. We performed a literature review searching for case reports and case series in order to offer evidence-based data for clinical management of these patients. Preexisting serological-only immune abnormalities or presence of a predisposing genetic background does not seem to confer significant risk but existing data is scarce. Most patients with preexistent autoimmune diseases can probably treated with checkpoint inhibitors as they seem to have at least the same response rate as the general cancer population. Under treatment, a significant part of them (at least 30%) can experience a flare of their baseline disease which can sometime be severe. Life-threatening cases seems rare and disease flare can be generally managed with steroids. The volume of available data is more important for rheumatologic diseases than for inflammatory bowel diseases were more caution should be observed. However, it has to be kept in mind that new immune related adverse effects (IrAE) are seen with a similar frequency as the flare of the baseline disease. Both flare-up's and newly developed IrAE are generally manageable with a careful clinical follow-up and prompt therapy., (Copyright © 2020 Coureau, Meert, Berghmans and Grigoriu.)
- Published
- 2020
- Full Text
- View/download PDF
41. Ethical climate and intention to leave among critical care clinicians: an observational study in 68 intensive care units across Europe and the United States.
- Author
-
Van den Bulcke B, Metaxa V, Reyners AK, Rusinova K, Jensen HI, Malmgren J, Darmon M, Talmor D, Meert AP, Cancelliere L, Zubek L, Maia P, Michalsen A, Kompanje EJO, Vlerick P, Roels J, Vansteelandt S, Decruyenaere J, Azoulay E, Vanheule S, Piers R, and Benoit D
- Subjects
- Adult, Attitude of Health Personnel, Critical Care psychology, Critical Care standards, Ethics, Medical, Europe, Female, Health Personnel statistics & numerical data, Humans, Intensive Care Units ethics, Intensive Care Units organization & administration, Intensive Care Units statistics & numerical data, Male, Surveys and Questionnaires, United States, Critical Care ethics, Health Personnel psychology, Intention, Organizational Culture
- Abstract
Purpose: Apart from organizational issues, quality of inter-professional collaboration during ethical decision-making may affect the intention to leave one's job. To determine whether ethical climate is associated with the intention to leave after adjustment for country, ICU and clinicians characteristics., Methods: Perceptions of the ethical climate among clinicians working in 68 adult ICUs in 12 European countries and the US were measured using a self-assessment questionnaire, together with job characteristics and intent to leave as a sub-analysis of the Dispropricus study. The validated ethical decision-making climate questionnaire included seven factors: not avoiding decision-making at end-of-life (EOL), mutual respect within the interdisciplinary team, open interdisciplinary reflection, ethical awareness, self-reflective physician leadership, active decision-making at end-of-life by physicians, and involvement of nurses in EOL. Hierarchical mixed effect models were used to assess associations between these factors, and the intent to leave in clinicians within ICUs, within the different countries., Results: Of 3610 nurses and 1137 physicians providing ICU bedside care, 63.1% and 62.9% participated, respectively. Of 2992 participating clinicians, 782 (26.1%) had intent to leave, of which 27% nurses, 24% junior and 22.7% senior physicians. After adjustment for country, ICU and clinicians characteristics, mutual respect OR 0.77 (95% CI 0.66- 0.90), open interdisciplinary reflection (OR 0.73 [95% CI 0.62-0.86]) and not avoiding EOL decisions (OR 0.87 [95% CI 0.77-0.98]) were all associated with a lower intent to leave., Conclusion: This is the first large multicenter study showing an independent association between clinicians' intent to leave and the quality of the ethical climate in the ICU. Interventions to reduce intent to leave may be most effective when they focus on improving mutual respect, interdisciplinary reflection and active decision-making at EOL.
- Published
- 2020
- Full Text
- View/download PDF
42. Direct admission to the intensive care unit from the emergency department and mortality in critically ill hematology patients.
- Author
-
Peyrony O, Chevret S, Meert AP, Perez P, Kouatchet A, Pène F, Mokart D, Lemiale V, Demoule A, Nyunga M, Bruneel F, Lebert C, Benoit D, Mirouse A, and Azoulay E
- Abstract
Background: The aim of this study was to assess the benefit of direct ICU admission from the emergency department (ED) compared to admission from wards, in patients with hematological malignancies requiring critical care., Methods: Post hoc analysis derived from a prospective, multicenter cohort study of 1011 critically ill adult patients with hematologic malignancies admitted to 17 ICU in Belgium and France from January 2010 to May 2011. The variable of interest was a direct ICU admission from the ED and the outcome was in-hospital mortality. The association between the variable of interest and the outcome was assessed by multivariable logistic regression after multiple imputation of missing data. Several sensitivity analyses were performed: complete case analysis, propensity score matching and multivariable Cox proportional-hazards analysis of 90-day survival., Results: Direct ICU admission from the ED occurred in 266 (26.4%) cases, 84 of whom (31.6%) died in the hospital versus 311/742 (41.9%) in those who did not. After adjustment, direct ICU admission from the ED was associated with a decreased in-hospital mortality (adjusted OR: 0.63; 95% CI 0.45-0.88). This was confirmed in the complete cases analysis (adjusted OR: 0.64; 95% CI 0.45-0.92) as well as in terms of hazard of death within the 90 days after admission (adjusted HR: 0.77; 95% CI 0.60-0.99). By contrast, in the propensity score-matched sample of 402 patients, direct admission was not associated with in-hospital mortality (adjusted OR: 0.92; 95% CI 0.84-1.01)., Conclusions: In this study, patients with hematological malignancies admitted to the ICU were more likely to be alive at hospital discharge if they were directly admitted from the ED rather than from the wards. Assessment of early predictors of poor outcome in cancer patients admitted to the ED is crucial so as to allow early referral to the ICU and avoid delays in treatment initiation and mis-orientation.
- Published
- 2019
- Full Text
- View/download PDF
43. Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review.
- Author
-
Wouters A, Durieux V, Kolivras A, Meert AP, and Sculier JP
- Subjects
- Biopsy, Blister pathology, Humans, Lupus Erythematosus, Systemic pathology, Middle Aged, Adenocarcinoma of Lung drug therapy, Blister chemically induced, Lung Neoplasms drug therapy, Lupus Erythematosus, Systemic chemically induced, Nivolumab adverse effects
- Abstract
Background: Various immune-related adverse events (irAEs) have been reported to be associated with the use of immune checkpoint inhibitors. We report a case of a patient with lung cancer treated with nivolumab who developed a bullous eruption and give a systematic review of the literature on irAEs in patients treated with immune checkpoint inhibitors for lung cancer., Case Report: A patient with lung adenocarcinoma developed a non-specific skin lesion at the time of his cancer diagnosis followed by flare episodes until the eighth cycle of nivolumab, when he developed a bullous lupus. As the first eruption had started a few months after his cancer diagnosis and was exacerbated during immunotherapy, a paraneoplastic origin is discussed. Since the patient also presented with flares under nivolumab, we reviewed reported irAEs. No bullous lupus was found but to date, 33 cases of paraneoplastic lupus and two of lupus erythematosus have been reported., Conclusion: To our knowledge, this is the first description of a bullous lupus exacerbated by nivolumab., (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
44. Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU.
- Author
-
Pistone A, Durieux V, Grigoriu B, and Meert AP
- Subjects
- Critical Illness mortality, Drug-Related Side Effects and Adverse Reactions, Guidelines as Topic, Humans, Intensive Care Units, Molecular Targeted Therapy mortality, Neoplasms mortality, Critical Illness therapy, Molecular Targeted Therapy adverse effects, Neoplasms drug therapy
- Abstract
Introduction: Targeted therapies, molecules in full expansion, are not free of side effects that can lead patients to intensive care. We performed an extensive review of the published evidence and propose a management strategy for acute complications of targeted therapy in critically ill patients with cancer., Methods: The literature search was performed in August 2017 using the Ovid Medline system by a scientific librarian and physicians. We made a review of cases admitted in intensive care unit (ICU) and a review of toxicities of grades greater or equal to 3., Results: Our search selected 59 articles. The main cardiovascular side effects requiring ICU are heart failure, which is generally reversible, severe hypertension, thrombotic and ischemic events, and rhythm disturbances. The main pulmonary side effects are interstitial lung disease essentially caused by crizotinib, respiratory infections, pneumothorax, and alveolar hemorrhage. The main gastrointestinal side effects are fulminant hepatitis that may be fatal, colitis that may be complicated by hemorrhage, and perforation. The main neurological side effect is posterior reversible encephalopathy syndrome essentially caused by bevacizumab. The main other side effects are Steven-Johnson syndrome, necrotizing fasciitis, and anaphylactic reactions., Conclusions: The side effects induced by targeted therapies may be fatal but are generally potentially reversible. The main treatment includes stopping current therapy and symptomatic management. Treatment rechallenge should be discussed on a case-by-case basis.
- Published
- 2019
- Full Text
- View/download PDF
45. Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies.
- Author
-
Mignard X, Biard L, Lemiale V, Mokart D, Pène F, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Rabbat A, Lebert C, Perez P, Meert AP, Benoit D, Hamidfar R, Darmon M, Azoulay E, and Zafrani L
- Subjects
- Aged, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Granulocyte Colony-Stimulating Factor adverse effects, Hematologic Neoplasms diagnosis, Humans, Intensive Care Units, Leukocyte Count, Male, Middle Aged, Neutropenia diagnosis, Neutropenia mortality, Propensity Score, Respiratory Distress Syndrome diagnosis, Respiratory Distress Syndrome etiology, Respiratory Distress Syndrome mortality, Respiratory Distress Syndrome therapy, Respiratory Function Tests, Treatment Outcome, Critical Illness, Granulocyte Colony-Stimulating Factor therapeutic use, Hematologic Neoplasms complications, Neutropenia drug therapy, Neutropenia etiology, Respiration drug effects
- Abstract
In patients with hematologic malignancies, respiratory status may deteriorate during neutropenia recovery. This multicenter, observational study aims to evaluate granulocyte colony-stimulating factor (G-CSF) impact on respiratory status in critically ill neutropenic patients. Among 1011 critically ill patients with hematologic malignancies, 288 were neutropenic and included in this study. 201 (70%) did not receive G-CSF at day 1 or 2. After propensity score matching for the probability of receiving G-CSF at day 1 or 2, there was no association between G-CSF and respiratory deterioration at day 14 (OR =1.19; 95%CI (0.57-2.51); p = .64). Additional sensitivity analysis in patients admitted for acute respiratory failure showed similar results (OR =1.34; 95%CI (0.5-3.59); p = .57). Among patients who recovered from neutropenia, 75% experienced respiratory deterioration during neutropenia recovery. This study confirms that neutropenia recovery is a situation at risk of respiratory deterioration. However, whether G-CSF is an aggravating factor cannot be supported by our results.
- Published
- 2019
- Full Text
- View/download PDF
46. [Lung cancer: Prognosis in intensive care depends mainly on the acute complication].
- Author
-
Gorham J, Ameye L, Paesmans M, Berghmans T, Sculier JP, and Meert AP
- Subjects
- Acute Disease, Adenocarcinoma mortality, Adenocarcinoma therapy, Adult, Aged, Aged, 80 and over, Female, Hospital Mortality, Humans, Intensive Care Units statistics & numerical data, Lung Neoplasms mortality, Lung Neoplasms therapy, Male, Middle Aged, Patient Admission statistics & numerical data, Patient Discharge statistics & numerical data, Prognosis, Respiratory Distress Syndrome etiology, Respiratory Distress Syndrome mortality, Respiratory Distress Syndrome therapy, Respiratory Insufficiency diagnosis, Respiratory Insufficiency mortality, Respiratory Insufficiency therapy, Retrospective Studies, Severity of Illness Index, Adenocarcinoma complications, Adenocarcinoma diagnosis, Critical Care statistics & numerical data, Lung Neoplasms complications, Lung Neoplasms diagnosis, Respiratory Distress Syndrome diagnosis
- Abstract
Introduction: It has been demonstrated in unselected populations of cancer patients that prognosis in intensive care is essentially dependent on the extent of the acute physiological disturbance caused by the complication precipitating the admission. By contrast, the prognosis after hospital discharge remains dependent on the characteristics of the underlying neoplasm. The aim of our study was to confirm whether this general finding was the case in a specific population of lung cancer patients, since there are no data on this patient group in the literature., Patients and Methods: We conducted a retrospective study including all patients with lung cancer admitted to our ICU between September 1, 2008 and December 31, 2013., Results: During this period, 180 different patients with lung cancer were admitted into ICU. The simplified acute physiology score II (SAPS II) (OR 1.07 ; 95% CI 1.04-1.11), respiratory failure (OR 4.00; 95% CI 1.76-9.07) and the presence of therapeutic limitations were the 3 factors independently affecting hospital mortality in multivariate analysis. Considering only patients discharged alive from the hospital, the presence of metastases (HR 2.30; 95% CI 1.44-3.65) and limitations on therapy (HR 5,89; IC 95% 3,11-11,14) were the two statistically independent prognostic factors for overall survival., Conclusion: In this population of lung cancer patients admitted into ICU, independent predictors of hospital mortality are determined by the physiological perturbations induced by the acute presenting complication. After recovery from this, prognosis is again determined by the characteristics of the underlying cancer., (Copyright © 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. Clinical Significance of Upper Airway Virus Detection in Critically Ill Hematology Patients.
- Author
-
Legoff J, Zucman N, Lemiale V, Mokart D, Pène F, Lambert J, Kouatchet A, Demoule A, Vincent F, Nyunga M, Bruneel F, Contejean A, Mercier-Delarue S, Rabbat A, Lebert C, Perez P, Meert AP, Benoit D, Schwebel C, Jourdain M, Darmon M, Resche-Rigon M, and Azoulay E
- Subjects
- Aged, Critical Illness, Female, Hematologic Diseases complications, Hematologic Diseases mortality, Hospital Mortality, Humans, Influenza, Human complications, Influenza, Human diagnosis, Influenza, Human mortality, Intensive Care Units, Male, Middle Aged, Multiplex Polymerase Chain Reaction, Paramyxoviridae Infections complications, Paramyxoviridae Infections diagnosis, Paramyxoviridae Infections mortality, Picornaviridae Infections complications, Picornaviridae Infections diagnosis, Picornaviridae Infections mortality, Respiratory Syncytial Virus Infections complications, Respiratory Syncytial Virus Infections diagnosis, Respiratory Syncytial Virus Infections mortality, Respiratory Tract Infections diagnosis, Respiratory Tract Infections mortality, Hematologic Diseases virology, Immunocompromised Host, Respiratory Tract Infections virology
- Abstract
Rationale: Noninvasive diagnostic multiplex molecular tests may enable the early identification and treatment of viral infections in critically ill immunocompromised patients., Objectives: To assess the association between viral detection in nasopharyngeal swabs and ICU mortality in critically ill hematology patients., Methods: This was a post hoc analysis of a prospective cohort of critically ill hematology patients admitted to 17 ICUs. Nasal swabs sampled and frozen at ICU admission were tested using a multiplex PCR assay. Predictors of ICU mortality and assay positivity were identified., Measurements and Main Results: Of the 747 patients (447 with acute respiratory failure [ARF]), 21.3% had a virus detected (56.4% rhinovirus/enterovirus and 30.7% influenza/parainfluenza/respiratory syncytial viruses). Overall ICU and hospital mortality rates were 26% and 37%, respectively. Assay positivity was associated with lymphoproliferative disorders, hematopoietic stem cell transplantation, treatment with steroids or other immunosuppressants, ARF (25.5% vs. 16.3%; P = 0.004), and death in the ICU (28.9% vs. 19.3%; P = 0.008). The association with ICU mortality was significant for all viruses and was strongest for influenza/parainfluenza/respiratory syncytial viruses. In patients with ARF, detection of any respiratory virus was independently associated with ICU mortality (odds ratio, 2.07; 95% confidence interval, 1.22-3.50)., Conclusions: Respiratory virus detection in the upper airway by multiplex PCR assay is common in critically ill hematology patients. In patients with ARF, respiratory virus detection was independently associated with ICU mortality. Multiplex PCR assay may prove helpful for the risk stratification of hematology patients with ARF. Studies to understand whether respiratory tract viruses play a causal role in outcomes are warranted.
- Published
- 2019
- Full Text
- View/download PDF
48. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
- Author
-
Lemiale V, Meert AP, Vincent F, Darmon M, Bauer PR, Van de Louw A, and Azoulay E
- Abstract
Checkpoint protein inhibitor antibodies (CPI), including cytotoxic T-lymphocyte-associated antigen 4 inhibitors (ipilimumab, tremelimumab) and the programmed cell death protein 1 pathway/programmed cell death protein 1 ligand inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab), have entered routine practice for the treatment of many cancers. They improve the outcome for many cancers, and more patients will be treated with CPI in the future. Although CPI can lead to adverse events (AE) less frequently than for chemotherapy, their use can require intensive care unit admission in case of severe immune-related adverse events (IrAE). Moreover, some of these events, particularly late events, are poorly documented, so a high level of suspicion should be maintained for patients receiving CPI. Intensivists should be aware in general of the known complications and appropriate management of these AE. Nevertheless, a multidisciplinary collaboration remains essential for their diagnosis and management. This review described the most severe complications related to CPI.
- Published
- 2019
- Full Text
- View/download PDF
49. Long-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study.
- Author
-
Ehooman F, Biard L, Lemiale V, Contou D, de Prost N, Mokart D, Pène F, Kouatchet A, Mayaux J, Demoule A, Vincent F, Nyunga M, Bruneel F, Rabbat A, Lebert C, Perez P, Meert AP, Benoit D, Hamidfar R, Darmon M, Azoulay E, and Zafrani L
- Abstract
Background: Although outcomes of critically ill patients with haematological malignancies (HMs) have been fully investigated in terms of organ failure and mortality, data are scarce on health-related quality of life (HRQOL) in this population. We aim to assess post-intensive care unit (ICU) burden and HRQOL of critically ill patients with HMs and to identify risk factors for quality-of-life (QOL) impairment., Results: In total, 1011 patients with HMs who required ICU admission in 17 ICUs in France and Belgium were included in the study; 278 and 117 patients were evaluated for QOL at 3 months and 1 year, respectively, after ICU discharge. HRQOL was determined by applying the interview form of the Short Form 36 (SF-36) questionnaire. Psychological distress symptoms were evaluated using the Hospital Anxiety Depression Score (HADS) and the Impact of Event Scale (IES). In-hospital mortality rates at 3 months and 1 year were, respectively, 39.1, 50.7 and 57.2%, respectively. At 3 months, median [IQR] physical and mental component summary scores (PCS and MCS) (SF-36) were 37 [28-46] and 51 [45-58], respectively. PCS was lower in ICU patients with HMs when compared to general ICU septic patients (52 [5-13], p = 0.00001). The median combined HAD score was 8 [5-13], and the median IES score was 8 [3-16]. However, recovery during the first year after ICU discharge was not consistent in all dimensions of HRQOL. Three months after ICU discharge, the maximum daily Sequential Organ Failure Assessment score and status of the underlying malignancy at ICU admission were significantly associated with MCS impairment (- 0.54 points [95% CI - 0.99; - 0.1], p = 0.018 and - 4.83 points [95% CI - 8.44; - 1.22], p = 0.009, respectively)., Conclusion: HRQOL is strongly impaired in critically ill patients with HMs at 3 months and 1 year after ICU discharge. Organ failure and disease status are strongly associated with QOL. The kinetic evaluation of QOL at 3 months and 1 year offers the opportunity to focus on QOL aspects that may be improved by therapeutic interventions during the first year after ICU discharge.
- Published
- 2019
- Full Text
- View/download PDF
50. ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.
- Author
-
Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, and Blum TG
- Subjects
- Advisory Committees, Data Collection, Denmark, Europe epidemiology, Humans, Interdisciplinary Communication, International Cooperation, Lung Neoplasms therapy, Medical Oncology trends, Quality of Health Care, Registries, Societies, Medical, United Kingdom, Lung Neoplasms diagnosis, Lung Neoplasms epidemiology, Medical Oncology standards
- Abstract
The European Respiratory Society (ERS) task force for harmonised standards for lung cancer registration and lung cancer services in Europe recognised the need to create a single dataset for use in pan-European data collection and a manual of standards for European lung cancer services.The multidisciplinary task force considered evidence from two different sources, reviewing existing national and international datasets alongside the results of a survey of clinical data collection on lung cancer in 35 European countries. A similar process was followed for the manual of lung cancer services, with the task force using existing guidelines and national or international recommendations for lung cancer services to develop a manual of standards for services in Europe.The task force developed essential and minimum datasets for lung cancer registration to enable all countries to collect the same essential data and some to collect data with greater detail. The task force also developed a manual specifying standards for lung cancer services in Europe.Despite the wide variation in the sociopolitical landscape across Europe, the ERS is determined to encourage the delivery of high-quality lung cancer care. Both the manual of lung cancer services and the minimum dataset for lung cancer registration will support this aspiration., Competing Interests: Conflict of interest: A.L. Rich has nothing to disclose. Conflict of interest: D.R. Baldwin reports personal fees for lecturing from AstraZeneca, outside the submitted work. Conflict of interest: P. Beckett has nothing to disclose. Conflict of interest: T. Berghmans has nothing to disclose. Conflict of interest: J. Boyd is an employee of the European Lung Foundation. Conflict of interest: C. Faivre-Finn reports research funding and business travel support from Merck, AstraZeneca and Pfizer, outside the submitted work. Conflict of interest: F. Galateau Salle has nothing to disclose. Conflict of interest: F. Gamarra has nothing to disclose. Conflict of interest: B. Grigoriu has nothing to disclose. Conflict of interest: N-C.G. Hansen has nothing to disclose. Conflict of interest: G. Hardavella has nothing to disclose. Conflict of interest: E. Jakobsen has nothing to disclose. Conflict of interest: D. Jovanovic has nothing to disclose. Conflict of interest: A. Konsoulova has nothing to disclose. Conflict of interest: G. Massard has nothing to disclose. Conflict of interest: J. McPhelim reports personal fees from Roche, MSD, Pfizer, Lilly Oncology and Abbvie, outside the submitted work. Conflict of interest: A-P. Meert has nothing to disclose. Conflict of interest: R. Milroy has nothing to disclose. Conflict of interest: L. Mutti has nothing to disclose. Conflict of interest: M. Paesmans has nothing to disclose. Conflict of interest: M.D. Peake has nothing to disclose. Conflict of interest: P.M. Putora has nothing to disclose. Conflict of interest: D.K.M. de Ruysscher has nothing to disclose. Conflict of interest: J-P. Sculier has nothing to disclose. Conflict of interest: A. Schepereel has nothing to disclose. Conflict of interest: D.R. Subotic has nothing to disclose. Conflict of interest: P. Van Schil has nothing to disclose. Conflict of interest: T.G. Blum has nothing to disclose., (Copyright ©ERS 2018.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.